NZ749019B2 - Anti-pd-l1 antibodies and uses thereof - Google Patents

Abstract

Provided are anti-PD-L1 antibodies or fragments thereof. The antibodies or fragments thereof specifically bind to the immunoglobulin C domain of the PD-L1 protein. In various example, the antibodies or fragments thereof include a VH CDR1 of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided. D NO: 3, a VL CDR1 of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6, or variants of each thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer and infectious diseases are also provided.

Description

ANTI-PD-Ll ANTIBODIES AND USES THEREOF BACKGROUND Programmed ligand l (PD-Ll), also known as cluster of entiation 274 (CD274) or B7 homolog 1 (B7-H1), is a 40kDa type 1 transmembrane protein ed to play a major role in suppressing the immune system during particular events such as pregnancy, tissue allografts, autoimmune disease and other disease states such as hepatitis. The binding of PD-Ll to PD-l or B7.1 transmits an inhibitory signal which reduces the proliferation of CD8+ T cells at the lymph nodes and supplementary to that PD-l is also able to control the accumulation of foreign n specific T cells in the lymph nodes through apoptosis which is further mediated by a lower regulation ofthe gene Bcl-2.

It has been shown that lation of PD-Ll may allow cancers to evade the host immune system. An analysis oftumor specimens from patients with renal cell carcinoma found that high tumor expression of PD-Ll was associated with increased tumor aggressiveness and an increased risk of death. Many PD-Ll inhibitors are in development as immuno-oncology therapies and are showing good results in al trials.

In addition to treatment of cancers, PD-Ll inhibition has also shown promises in treating infectious diseases. In a mouse model of intracellular infection, L. monocytogenes induced PD- Ll protein expression in T cells, NK cells, and macrophages. PD-Ll blockade (e.g., using blocking antibodies) resulted in increased mortality for infected mice. Blockade reduced TNFa and nitric oxide production by macrophages, reduced me B tion by NK cells, and decreased eration of L. monocytogenes antigen-specific CD8 T cells (but not CD4 T .

This evidence suggests that PD-Ll acts as a positive ulatory molecule in intracellular infection.

The present disclosure provides anti-PD-Ll antibody having high binding affinity to human PD-Ll proteins and can effectively block the interaction between PD-Ll and its receptor PD-l. Also importantly, the examples demonstrate that these anti-PD-Ll antibodies promote T cell immune response and inhibit tumor growth. Different from known anti-PD-Ll antibodies [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] r Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar ionNone set by wilksar [Annotation] wilksar Unmarked set by wilksar that bind to the immunoglobulin V domain of the extracellular portion of the PD-Ll protein, these antibodies bind to the immunoglobulin C domain, in particular amino acid es Yl34, K162, and N183. These anti-PD-Ll antibodies are usefiil for therapeutic purposes such as treating various types of cancer, as well as infections, and can also be used for diagnostic and prognostic purposes.

One ment of the present disclosure provides an anti-PD-Ll antibody or fragment thereof, which antibody or fragment thereof can specifically bind to an immunoglobulin C (Ig C) domain of a human Programmed death-ligand 1 (PD-L1) protein. In some embodiments, the Ig C domain consists of amino acid residues 133-225. In some embodiments, the antibody or fragment thereof can bind to at least one of amino acid residues Yl34, K162, or N183 of the PD-Ll protein. In some embodiments, the antibody or fragment thereof can bind to at least one of amino acid residues Yl34, K162, and N183 of the PD-Ll protein. In some embodiments, the antibody or fragment thereof does not bind to an immunoglobulin V (Ig V) domain of the PD-Ll protein, wherein the Ig V domain ts of amino acid residues 19-127.

One embodiment of the present sure provides an anti-PD-Ll antibody or fragment f, wherein the antibody or fragment thereof has specificity to a human Programmed death- ligand 1 (PD-L1) protein and comprises a VH CDRl of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDRl of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6. In some embodiments, the antibody or fragment thereof fithher comprises a heavy chain constant region, a light chain constant , an Fc region, or the combination thereof. In some embodiments, the light chain constant region is a kappa or lambda chain constant region. In some embodiments, the antibody or nt thereof is of an isotype of IgG, IgM, IgA, IgE or IgD. In some embodiments, the e is IgGl, IgG2, IgG3 or IgG4. t limitation, the antibody or fragment thereof is a chimeric antibody, a humanized antibody, or a fiilly human antibody. In one aspect, dy or fragment thereof is a humanized antibody.

In some ments, the antibody or fragment thereof comprises a heavy chain variable region sing one or more amino acid residues selected from the group consisting of (a) Ser at position 44, (b) Ala at position 49, (c) Ala at position 53, (d) Ile at position 91, (e) Glu at position 1, (f) Val at position 37, (g) Thr at position 40 (h) Val at position 53, (i) Glu at D ation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] r Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar on 54, (j) Asn at position 77, (k) Arg at position 94, and (l) Thr at position 108, according to Kabat numbering, and combinations thereof. In some embodiments, the antibody or fragment thereof comprises a heavy chain variable region comprising (a) Ser at position 44, (b) Ala at position 49, (c) Ala at position 53, and/or (d) Ile at position 91, according to Kabat numbering, and combinations thereof.

In some embodiments, the antibody or fragment thereof comprises a light chain variable region comprising one or more amino acid residues selected from the group ting of: (a) Ser at position 22, (b) Gln at position 42, (c) Ser at position 43, (d) Asp at position 60, and (e) Thr at position 63, according to Kabat numbering, and combinations thereof.

Non-limiting examples of antibody or fragment thereof include those having a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 7-26, or a peptide having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 7-26. miting examples of antibody or fragment thereof include those having a light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 27-33, or a peptide having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO: 27-33. Non-limiting es of antibody or nt thereof e those having a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 20 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 28.

Biologically equivalent ts ofthe antibodies and fragments thereof are also described. In some embodiments, provided is an isolated dy or fragment f, n the antibody or fragment thereof has specificity to a human PD-Ll protein and comprises: (a) a VH CDRl of SEQ ID NO: 1, or a t of SEQ ID NO: 1 having a single substitution, deletion or insertion at location 1, 2 or 5 of SEQ ID NO: 1, (b) a VH CDR2 of SEQ ID NO: 2, or a variant of SEQ ID NO: 2 having a single substitution, deletion or insertion at location 7, 8, 14 or of SEQ ID NO: 2, (c) a VH CDR3 of SEQ ID NO: 3, or a variant of SEQ ID NO: 3 having a single substitution, deletion or ion at location 1, 2, 3, 4, 5 or 6 of SEQ ID NO: 3, (d) a VL CDRl of SEQ ID NO: 4, or a variant of SEQ ID NO: 4 having a single substitution, deletion or insertion at location 3 of SEQ ID NO: 4, (e) a VL CDR2 of SEQ ID NO: 5, or a variant of SEQ ID NO: 5 having a single substitution, deletion or insertion at location 1, 2, 3, 4, 5 or 6 of SEQ D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar ionNone set by wilksar [Annotation] wilksar ed set by wilksar ID NO: 5 and (f) a VL CDR3 of SEQ ID NO: 6, or a variant of SEQ ID NO: 6 having a single substitution, deletion or insertion at location 11 or 2 of SEQ ID NO: 6.

In some embodiments, the valiant of SEQ ID NO: 1 is selected from the group consisting of SEQ ID NO: 61-67. In some embodiments, the t of SEQ ID NO: 2 is selected from the group consisting of SEQ ID NO: 68-77. In some embodiments, the variant of SEQ ID NO: 3 is selected from the group consisting of SEQ ID NO: 78-90. In some embodiments, the variant of SEQ ID NO: 4 is selected from the group consisting of SEQ ID NO: 91-92. In some embodiments, the variant of SEQ ID NO: 5 is selected from the group consisting of SEQ ID NO: 93-105. In some embodiments, the variant of SEQ ID NO: 6 is selected from the group consisting of SEQ ID NO: 106-111.

In some embodiments, the antibody or fragment thereof ses a heavy chain variable region sing one or more amino acid residues selected from the group consisting of (a) Ser at position 44, (b) Ala at position 49, (c) Ala at on 53, (d) Ile at position 91, (e) Glu at position 1, (f) Val at on 37, (g) Thr at position 40 (h) Val at position 53, (i) Glu at position 54, (j) Asn at position 77, (k) Arg at position 94, and (l) Thr at position 108, according to Kabat numbering, and ations thereof. In some embodiments, the antibody or fragment thereof comprises a heavy chain variable region comprising (a) Ser at position 44, (b) Ala at position 49, (c) Ala at position 53, and/or (d) Ile at position 91, according to Kabat numbering, and combinations f.

In some embodiments, the antibody or fragment thereof comprises a light chain variable region comprising one or more amino acid residues selected from the group consisting of: (a) Ser at position 22, (b) Gln at position 42, (c) Ser at position 43, (d) Asp at position 60, and (e) Thr at position 63, according to Kabat numbering, and combinations thereof.

Also ed, in some embodiments, is a composition comprising the antibody or fragment thereof of the present disclosure and a pharmaceutically able carrier. Still also provided, in some embodiments, is an isolated cell comprising one or more polynucleotide ng the antibody or fragment f ofthe present disclosure.

Treatment methods and uses are also provided. In one embodiment, a method oftreating cancer or infection in a patient in need thereof is provided, comprising administering to the D [Annotation] wilksar None set by wilksar [Annotation] r MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar patient an effective amount ofthe antibody or fragment thereof of the present disclosure. In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is ed from the group consisting of bladder cancer, liver cancer, colon cancer, rectal cancer, endometrial cancer, leukemia, ma, pancreatic cancer, small cell lung cancer, non-small cell lung , breast cancer, urethral cancer, head and neck cancer, gastrointestinal , stomach cancer, oesophageal cancer, ovarian cancer, renal cancer, melanoma, prostate cancer and thyroid cancer. In some embodiments, the cancer is selected from the group consisting of bladder , liver cancer, pancreatic cancer, non-small cell lung cancer, breast cancer, urethral cancer, colorectal cancer, head and neck cancer, squamous cell cancer, Merkel cell carcinoma, gastrointestinal cancer, stomach cancer, oesophageal cancer, ovarian cancer, renal cancer, and small cell lung cancer. In some embodiments, the method fithher comprises administering to the patient a second cancer therapeutic agent. In some embodiments, the infection is viral infection, bacterial infection, fungal infection or infection by a parasite.

In another embodiment, a method oftreating cancer or infection in a patient in need f is provided, comprising: (a) treating a cell, in vitro, with the antibody or fragment thereof ofthe present disclosure, and (b) stering the treated cell to the patient. In some embodiments, the method fithher ses, prior to step (a), isolating the cell from an individual. In some embodiments, the cell is isolated from the patient. In some embodiments, the cell is isolated from a donor individual different from the t. In some embodiments, the cell is a T cell, non-limiting examples of which include a tumor-infiltrating T lymphocyte, a CD4+ T cell, a CD8+ T cell, or the combination thereof.

Diagnostic methods and uses are also provided. In one embodiment, a method of detecting sion of PD-Ll in a sample is provided, comprising contacting the sample with an antibody or fragment thereof under conditions for the antibody or fragment f to bind to the PD-Ll, and ing the binding which indicates sion of PD-Ll in the sample. In some embodiments, the sample comprises a tumor cell, a tumor tissue, an infected tissue, or a blood sample.

Antibodies and fragment ofthe present disclosure can be used to prepare bispecific antibodies. In one embodiment, an isolated bispecific antibody is provided, sing a nt of the present sure and a second antigen-binding fragment having specificity to a D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar molecular on an immune cell. In some embodiments, the molecule is ed from the group ting of PD-l, CTLA-4, LAG-3, CD28, CD122, 4-1BB, TIM3, OX-40, OX40L, CD40, CD40L, LIGHT, ICOS, ICOSL, GITR, GITRL, TIGIT, CD27, VISTA, B7H3, B7H4, HEVM or BTLA, CD47 and CD73. In some embodiments, the fragment and the second fragment each is independently selected from a Fab fragment, a single-chain variable fragment (scFV), or a single-domain antibody. In some embodiments, the bispecific antibody further comprises a Fc fragment.

BRIEF PTION OF THE DRAWINGS shows that HLl210-3 can bind to human PD-Ll with high affinity. shows that HLl210-3 can efficiently inhibit the binding ofhuman PD-Ll to human PD 1. shows the HLl210-3 antibody can highly efficiently t the binding of PD-l on PD-Ll expressed on mammalian cells. shows that the tested D-Ll antibodies can promote human T cell response. shows the g kinetics ofHLl210-3 to recombinant PD-Ll. shows that all tested humanized antibodies had comparable binding efficacy to human PD-Ll in contact to chimeric antibody. shows that all tested humanized antibodies can high efficiently bind to PD-Ll eXpressed on mammalian cells, comparable with chimeric antibody. shows that humanized antibody Hul210-4l can bind to rhesus PD-Ll with lower affinity and cannot bind to rat and mouse PD-Ll. shows that -4l antibody can only specifically binding to B7-Hl (PD-Ll), not B7-DC, B7-l, B7-2, B7-H2, PD-l, CD28, CTLA4, ICOS and BTLA. shows that Hul210-4l can efficiently inhibit the binding of human PD-Ll to human PDl and B7-l.

D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] r Unmarked set by wilksar [Annotation] r None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar shows that Hu1210-4l can efficiently t the binding of human PD-Ll to human PDl and B7-l. shows that the Hu1210-8, Hu1210-9, -16, Hu1210-17, Hu1210-21 and Hu1210-36 humanized antibodies can dose dependently promote the IFNy and IL-2 production in mix lymphocyte on. shows that the Hu1210-40, Hu1210-4l and Hu1210-l7 humanized antibodies can dose dependently promote the IFNy production in CMV recall assay. shows that Hu1210-31 can inhibit the tumor growth by 30% at 5mg/kg in HCC827-NSG-xenograft model. shows that Hu1210-4l antibody can dose-dependently inhibit the tumor growth in HCC827-NSG-xenograft model, while the tumor weight was also dose-dependently suppressed by Hu1210-4l antibody. plots, for each PD-Ll mutant, the mean binding value as a fill’lCthl’l of expression (control anti-PD-Ll mAb reactivity). illustrates the locations of Y134, K162, and N183, the residues (spheres) involved in binding to the D-Ll -4l antibody.

DETAILED DESCRIPTION Definitions It is to be noted that the term “a” or “an” entity refers to one or more of that entity, for example, “an antibody,” is understood to represent one or more antibodies. As such, the terms “a” (or “an”), “one or more,” and “at least one” can be used interchangeably herein.

As used herein, the term “polypeptide” is ed to encompass a singular “polypeptide” as well as plural “polypeptides,” and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as e bonds). The term “polypeptide” refers to any chain or chains oftwo or more amino acids, and does not refer to a specific length ofthe product. Thus, peptides, dipeptides, tripeptides, oligopeptides, “protein,” B [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar “amino acid ” or any other term used to refer to a chain or chains of two or more amino acids, are included within the definition of “polypeptide,” and the term eptide” may be used instead of, or interchangeably with any of these terms. The term “polypeptide” is also intended to refer to the products of post-expression modifications of the polypeptide, ing without limitation glycosylation, acetylation, phosphorylation, ion, derivatization by known protecting/blocking groups, proteolytic ge, or modification by non- naturally occurring amino acids. A polypeptide may be derived from a natural ical source or produced by recombinant technology, but is not necessarily translated from a designated nucleic acid sequence. It may be generated in any manner, including by chemical synthesis.

The term “isolated” as used herein with respect to cells, nucleic acids, such as DNA or RNA, refers to molecules separated from other DNAs or RNAs, respectively, that are present in the natural source ofthe macromolecule. The term “isolated” as used herein also refers to a nucleic acid or e that is ntially free of cellular material, viral material, or e medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Moreover, an “isolated c acid” is meant to include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state. The term “isolated” is also used herein to refer to cells or polypeptides which are isolated from other ar proteins or tissues. Isolated polypeptides is meant to encompass both d and recombinant polypeptides.

As used herein, the term “recombinant” as it pertains to polypeptides or polynucleotides intends a form of the polypeptide or polynucleotide that does not eXist naturally, a non-limiting example ofwhich can be created by combining polynucleotides or polypeptides that would not ly occur together.

“Homology” or “identity” or “similarity” refers to sequence similarity between two peptides or between two nucleic acid les. Homology can be determined by comparing a position in each ce which may be aligned for purposes of comparison. When a position in the compared sequence is occupied by the same base or amino acid, then the molecules are homologous at that position. A degree ofhomology between sequences is a function of the number ofmatching or homologous positions shared by the sequences. An “unrelated” or “non- D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r homologous” sequence shares less than 40% identity, though preferably less than 25% identity, with one of the ces of the present disclosure.

A polynucleotide or cleotide region (or a polypeptide or polypeptide region) has a certain percentage (for example, 60 %, 65 %, 70 %, 75 %, 80 %, 85 %, 90 %, 95 %, 98 % or 99 %) of “sequence identity” to another sequence means that, when aligned, that percentage of bases (or amino acids) are the same in comparing the two sequences. This alignment and the percent homology or sequence identity can be determined using software programs known in the art, for example those described in Ausubel et al. eds. (2007) Current Protocols in Molecular Biology. Preferably, default parameters are used for alignment. One alignment program is BLAST, using default ters. In particular, programs are BLASTN and BLASTP, using the following default parameters: Genetic code = standard, filter = none, strand = both, cutoff = 60, expect = 10, Matrix = BLOSUM62, Descriptions = 50 sequences, sort by = HIGH SCORE, Databases = non-redundant, GenBank + EMBL + DDBJ + PDB + GenBank CDS translations + SwissProtein + SPupdate + PIR. Biologically equivalent polynucleotides are those having the above-noted specified percent homology and encoding a polypeptide having the same or similar biological activity.

The term “an equivalent nucleic acid or polynucleotide” refers to a nucleic acid having a nucleotide sequence having a certain degree of gy, or sequence identity, with the tide ce ofthe nucleic acid or complement thereof. A homolog of a double stranded nucleic acid is intended to include nucleic acids having a tide sequence which has a certain degree of homology with or with the complement thereof. In one , homologs of nucleic acids are e of hybridizing to the c acid or ment f. Likewise, “an equivalent polypeptide” refers to a polypeptide having a certain degree of gy, or sequence identity, with the amino acid sequence of a reference polypeptide. In some aspects, the sequence identity is at least about 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%. In some aspects, the equivalent polypeptide or polynucleotide has one, two, three, four or five addition, deletion, substitution and their combinations thereof as compared to the reference polypeptide or polynucleotide. In some aspects, the equivalent sequence s the activity (e.g., epitope- g) or structure (e.g., salt-bridge) of the reference sequence.

D [Annotation] r None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] r ed set by wilksar Hybridization reactions can be performed under ions of different “stringency”. In general, a low stringency hybridization reaction is carried out at about 40°C in about 10 X SSC or a on of equivalent ionic strength/temperature. A moderate stringency hybridization is typically performed at about 50°C in about 6 X SSC, and a high stringency hybridization reaction is generally performed at about 60°C in about 1 X SSC. ization ons can also be performed under “physiological conditions” which is well known to one of skill in the art. A non-limiting example of a physiological condition is the temperature, ionic strength, pH and tration of Mg2+ normally found in a cell.

A polynucleotide is composed of a specific sequence of four nucleotide bases: e (A), cytosine (C), guanine (G), thymine (T), and uracil (U) for thymine when the polynucleotide is RNA. Thus, the term “polynucleotide sequence” is the etical representation of a polynucleotide molecule. This alphabetical representation can be input into databases in a computer haVing a central processing unit and used for bioinformatics applications such as fiinctional genomics and homology searching. The term “polymorphism” refers to the coeXistence ofmore than one form of a gene or portion thereof. A n of a gene of which there are at least two different forms, i.e., two different nucleotide ces, is referred to as a “polymorphic region of a gene”. A polymorphic region can be a single nucleotide, the identity ofwhich differs in different alleles.

The terms “polynucleotide” and “oligonucleotide” are used hangeably and refer to a polymeric form of nucleotides of any length, either de0Xyribonucleotides or ribonucleotides or analogs thereof. Polynucleotides can have any three-dimensional structure and may perform any fiinction, known or unknown. The following are non-limiting eXamples of polynucleotides: a gene or gene nt (for eXample, a probe, primer, EST or SAGE tag), eX0ns, introns, messenger RNA (mRNA), er RNA, ribosomal RNA, ribozymes, cDNA, dsRNA, siRNA, miRNA, recombinant polynucleotides, ed polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. A polynucleotide can comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs. If present, modifications to the nucleotide structure can be imparted before or after assembly of the polynucleotide. The sequence of nucleotides can be interrupted by non-nucleotide components. A polynucleotide can be fithher modified after polymerization, such as by conjugation with a labeling component. The term also refers to both double- and D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar ation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar single-stranded molecules. Unless otherwise specified or required, any embodiment of this disclosure that is a polynucleotide encompasses both the double-stranded form and each oftwo complementary single-stranded forms known or predicted to make up the -stranded form.

The term “encode” as it is applied to polynucleotides refers to a polynucleotide which is said to “encode” a polypeptide if, in its native state or when lated by methods well known to those skilled in the art, it can be transcribed and/or translated to produce the mRNA for the ptide and/or a fragment thereof. The antisense strand is the complement of such a nucleic acid, and the encoding sequence can be deduced therefrom.

As used herein, an “antibody” or “antigen-binding polypeptide” refers to a polypeptide or a polypeptide compleX that specifically izes and binds to an antigen. An dy can be a whole antibody and any antigen binding nt or a single chain f. Thus the term “antibody” includes any protein or peptide containing le that comprises at least a portion of an immunoglobulin molecule having biological ty of binding to the antigen. Examples of such include, but are not d to a complementarity determining region (CDR) of a heavy or light chain or a ligand binding n thereof, a heavy chain or light chain variable region, a heavy chain or light chain constant region, a ork (FR) region, or any portion thereof, or at least one portion of a binding protein.

The terms “antibody fragment” or “antigen-binding fragment”, as used herein, is a portion of an antibody such as F(ab')2, F(ab)2, Fab', Fab, Fv, scFv and the like. Regardless of structure, an antibody fragment binds with the same antigen that is recognized by the intact antibody. The term “antibody fragment” includes aptamers, spiegelmers, and diabodies. The term “antibody fragment” also includes any synthetic or genetically engineered protein that acts like an antibody by binding to a specific antigen to form a compleX.

A “single-chain variable fragment” or “scFv” refers to a fusion protein of the variable regions of the heavy (VH) and light chains (VL) of immunoglobulins. In some aspects, the regions are connected with a short linker peptide often to about 25 amino acids. The linker can be rich in e for flexibility, as well as serine or threonine for solubility, and can either connect the N—terminus of the VH with the C-terminus of the VL, or vice versa. This protein retains the specificity of the al immunoglobulin, despite removal ofthe constant regions D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar ation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar and the introduction of the . ScFv molecules are known in the art and are described, e.g., in US patent 5,892,019.

The term antibody encompasses various broad classes of polypeptides that can be distinguished biochemically. Those skilled in the art will appreciate that heavy chains are classified as gamma, mu, alpha, delta, or epsilon (y, u, 0c, 8, 8) with some subclasses among them (e.g., y l- y4). It is the nature of this chain that ines the “class” of the antibody as IgG, IgM, IgA IgG, or IgE, respectively. The immunoglobulin subclasses (isotypes) e.g., IgGi, IgG2, IgG3, IgG4, IgGs, etc. are well characterized and are known to confer onal specialization. Modified versions of each of these classes and isotypes are readily discemable to the skilled artisan in view of the instant disclosure and, accordingly, are within the scope of the instant sure. All immunoglobulin classes are clearly within the scope of the present sure, the following discussion will generally be directed to the IgG class of immunoglobulin molecules. With regard to IgG, a standard immunoglobulin molecule comprises two cal light chain polypeptides of molecular weight approximately 23,000 Daltons, and two identical heavy chain polypeptides of molecular weight 53,000-70,000. The four chains are typically joined by disulfide bonds in a “Y” configuration wherein the light chains bracket the heavy chains starting at the mouth ofthe “Y” and continuing h the variable region.

Antibodies, antigen-binding polypeptides, variants, or derivatives thereof of the disclosure include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized, ized, or chimeric antibodies, single chain antibodies, epitope-binding fragments, e.g., Fab, Fab' and F(ab')2, Fd, Fvs, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (dev), fragments comprising either a VK or VH domain, fragments produced by a Fab eXpression library, and anti- pic (anti-Id) antibodies (including, e.g., anti-Id antibodies to LIGHT antibodies sed herein). Immunoglobulin or antibody molecules of the disclosure can be of any type (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgGl, IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule.

Light chains are classified as either kappa or lambda (K, k). Each heavy chain class may be bound with either a kappa or lambda light chain. In general, the light and heavy chains are covalently bonded to each other, and the “tail” portions of the two heavy chains are bonded to D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r ation] wilksar Unmarked set by wilksar ation] wilksar None set by wilksar ation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar each other by covalent disulfide linkages or non-covalent linkages when the immunoglobulins are generated either by hybridomas, B cells or genetically engineered host cells. In the heavy chain, the amino acid sequences run from an inus at the forked ends ofthe Y configuration to the inus at the bottom of each chain.

Both the light and heavy chains are divided into regions of structural and fiinctional homology. The terms “constant” and “variable” are used onally. In this regard, it will be appreciated that the variable domains of both the light (VK) and heavy (VH) chain portions ine antigen recognition and specificity. Conversely, the constant domains of the light chain (CK) and the heavy chain (CH1, CH2 or CH3) confer important biological properties such as secretion, transplacental mobility, Fc receptor binding, complement binding, and the like. By convention the numbering of the constant region domains increases as they become more distal from the antigen-binding site or amino- us ofthe antibody. The N-terminal portion is a variable region and at the C-terminal portion is a constant region, the CH3 and CK domains actually se the carboxy-terminus ofthe heavy and light chain, tively.

As indicated above, the variable region allows the antibody to selectively ize and specifically bind epitopes on antigens. That is, the VK domain and VH domain, or subset of the complementarity determining regions (CDRs), of an antibody combine to form the variable region that defines a three dimensional antigen-binding site. This quaternary antibody structure forms the antigen-binding site present at the end of each arm of the Y. More specifically, the antigen-binding site is defined by three CDRs on each ofthe VH and VK chains (Le. CDR-Hl, CDR-H2, CDR-H3, CDR—Ll, CDR—L2 and CDR—L3). In some instances, e.g., certain immunoglobulin molecules derived from camelid species or engineered based on camelid immunoglobulins, a complete immunoglobulin molecule may consist ofheavy chains only, with no light . See, e.g., Hamers-Casterman er al., Nature 363:446-448 (1993).

In naturally occurring antibodies, the siX “complementarity determining regions” or “CDRs” present in each antigen-binding domain are short, non-contiguous sequences of amino acids that are cally positioned to form the antigen-binding domain as the antibody assumes its three dimensional configuration in an s environment. The remainder of the amino acids in the antigen-binding domains, referred to as “framework” regions, show less inter- molecular variability. The framework regions largely adopt a B-sheet conformation and the D [Annotation] wilksar None set by wilksar ation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar ation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar CDRs form loops which connect, and in some cases form part of, the [3 -sheet structure. Thus, framework regions act to form a scaffold that provides for positioning the CDRs in correct orientation by inter-chain, non-covalent interactions. The antigen-binding domain formed by the positioned CDRs defines a surface complementary to the epitope on the reactive antigen. This complementary surface promotes the non-covalent binding of the antibody to its e epitope. The amino acids comprising the CDRs and the framework regions, respectively, can be readily identified for any given heavy or light chain variable region by one of ordinary skill in the art, since they have been precisely defined (see “Sequences of Proteins of Immunological Interest,” Kabat, E., et al., US. ment of Health and Human Services, (1983), and Chothia and Lesk, J. M01. Biol, 196:901-917 (1987)).

In the case where there are two or more definitions of a term which is used and/or accepted within the art, the definition of the term as used herein is intended to include all such meanings unless eXplicitly stated to the contrary. A specific example is the use of the term “complementarity ining region” (“CDR”) to describe the non-contiguous antigen combining sites found within the variable region of both heavy and light chain polypeptides.

This particular region has been described by Kabat et al., US. Dept. of Health and Human Services, “Sequences of ns of Immunological Interest” (1983) and by Chothia et al., J.

M01. Biol. 196:901-917 , which are incorporated herein by reference in their entireties.

The CDR tions according to Kabat and Chothia include overlapping or subsets of amino acid residues when compared against each other. Nevertheless, application of either definition to refer to a CDR of an antibody or variants thereof is intended to be within the scope ofthe term as defined and used herein. The appropriate amino acid residues which encompass the CDRs as defined by each of the above cited references are set forth in the table below as a comparison. The exact residue numbers which encompass a particular CDR will vary depending on the sequence and size of the CDR. Those d in the art can routinely ine which residues se a particular CDR given the variable region amino acid ce of the antibody.

[Annotation] wilksar None set by wilksar [Annotation] r MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r Kabat Chothia CDR-H1 31-35 26-32 CDR-H2 CDR-H3 CDR-Ll CDR-L2 CDR-L3 Kabat et al. also defined a numbering system for variable domain sequences that is applicable to any antibody. One of ordinary skill in the art can unambiguously assign this system of “Kabat numbering” to any variable domain sequence, without reliance on any experimental data beyond the sequence itself. As used herein, “Kabat numbering” refers to the numbering system set forth by Kabat et al., US. Dept. of Health and Human es, “Sequence of Proteins of Immunological Interest” (1983).

In addition to table above, the Kabat number system describes the CDR s as follows: CDR-H1 begins at approximately amino acid 31 (i.e., imately 9 residues after the first cysteine residue), includes approximately 5-7 amino acids, and ends at the next phan residue. CDR-H2 begins at the fifteenth residue after the end of CDR-H1, includes approximately 16-19 amino acids, and ends at the next arginine or lysine residue. CDR-H3 begins at approximately the thirty third amino acid e after the end of CDR-H2, includes 3- amino acids, and ends at the sequence W-G-X-G, where X is any amino acid. CDR-Ll begins at approximately residue 24 (i.€., following a cysteine residue), includes approximately -17 residues, and ends at the next tryptophan residue. CDR-L2 begins at approximately the sixteenth residue after the end of CDR-Ll and includes approximately 7 es. CDR-L3 begins at approximately the thirty third residue after the end of CDR-L2 (i.e., following a cysteine residue), includes approximately 7-11 residues and ends at the sequence F or W-G-X- G, where X is any amino acid.

Antibodies disclosed herein may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine, donkey, , goat, guinea pig, camel, llama, horse, or chicken antibodies. In another embodiment, the le region may be condricthoid in origin (e.g., from sharks).

D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] wilksar Unmarked set by wilksar ation] wilksar None set by wilksar ation] wilksar ionNone set by wilksar [Annotation] wilksar Unmarked set by wilksar As used herein, the term “heavy chain constant region” es amino acid sequences derived from an immunoglobulin heavy chain. A polypeptide comprising a heavy chain constant region comprises at least one of: a CHl domain, a hinge (e. g., upper, middle, and/or lower hinge region) domain, a CH2 domain, a CH3 domain, or a variant or fragment thereof.

For example, an antigen-binding ptide for use in the disclosure may comprise a polypeptide chain comprising a CHl domain, a polypeptide chain comprising a CHl domain, at least a portion of a hinge domain, and a CH2 domain, a polypeptide chain comprising a CHl domain and a CH3 , a polypeptide chain comprising a CHl domain, at least a portion of a hinge domain, and a CH3 , or a polypeptide chain sing a CHl domain, at least a portion of a hinge , a CH2 domain, and a CH3 domain. In another embodiment, a polypeptide of the disclosure comprises a polypeptide chain comprising a CH3 domain. Further, an antibody for use in the disclosure may lack at least a portion of a CH2 domain (e.g., all or part of a CH2 domain). As set forth above, it will be understood by one of ordinary skill in the art that the heavy chain constant region may be modified such that they vary in amino acid sequence from the naturally occurring immunoglobulin le.

The heavy chain constant region of an antibody disclosed herein may be derived from different immunoglobulin molecules. For example, a heavy chain constant region of a polypeptide may comprise a CHl domain derived from an IgG1 molecule and a hinge region derived from an IgG3 molecule. In another example, a heavy chain constant region can comprise a hinge region derived, in part, from an IgG1 molecule and, in part, from an IgG3 molecule. In another example, a heavy chain portion can comprise a chimeric hinge derived, in part, from an IgG1 molecule and, in part, from an IgG4 molecule.

As used , the term “light chain constant region” includes amino acid sequences d from antibody light chain. Preferably, the light chain constant region comprises at least one of a constant kappa domain or nt lambda domain.

A “light chain-heavy chain pair” refers to the collection of a light chain and heavy chain that can form a dimer through a disulfide bond between the CL domain of the light chain and the CH1 domain of the heavy chain.

As previously indicated, the subunit structures and three dimensional configuration of the constant s of the various immunoglobulin classes are well known. As used herein, the D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar term “VH domain” includes the amino terminal variable domain of an immunoglobulin heavy chain and the term “CH1 ” es the first (most amino terminal) constant region domain of an immunoglobulin heavy chain. The CH1 domain is adjacent to the VH domain and is amino terminal to the hinge region of an immunoglobulin heavy chain molecule.

As used herein the term “CH2 domain” es the portion of a heavy chain molecule that extends, e.g., from about residue 244 to residue 360 of an antibody using conventional numbering schemes (residues 244 to 360, Kabat numbering system; and es 231-340, EU numbering system; see Kabat et al., US. Dept. of Health and Human Services, “Sequences of Proteins of Immunological Interest” (1983). The CH2 domain is unique in that it is not y paired with another domain. , two N—linked branched carbohydrate chains are interposed between the two CH2 domains of an intact native IgG molecule. It is also well documented that the CH3 domain extends from the CH2 domain to the C-terminal of the IgG molecule and comprises approximately 108 residues.

As used herein, the term “hinge region” includes the portion of a heavy chain molecule that joins the CH1 domain to the CH2 domain. This hinge region comprises approximately 25 es and is flexible, thus allowing the two N-terminal n-binding regions to move independently. Hinge regions can be subdivided into three distinct domains: upper, middle, and lower hinge domains (Roux er al., J. Immunol 83 (1998)).

As used herein the term “disulfide bond” es the covalent bond formed between two sulfiJr atoms. The amino acid cysteine comprises a thiol group that can form a disulfide bond or bridge with a second thiol group. In most naturally occurring IgG molecules, the CH1 and CK regions are linked by a disulfide bond and the two heavy chains are linked by two disulfide bonds at positions corresponding to 239 and 242 using the Kabat numbering system (position 226 or 229, EU numbering system).

As used herein, the term “chimeric antibody” will be held to mean any antibody wherein the immunoreactive region or site is obtained or derived from a first species and the constant region (which may be intact, partial or d in accordance with the instant sure) is obtained from a second species. In certain embodiments the target binding region or site will be from a non-human source (6.g. mouse or primate) and the constant region is human.

B [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar As used herein, “percent humanization” is calculated by determining the number of framework amino acid differences (i.€., non-CDR difference) between the humanized domain and the germline domain, subtracting that number from the total number of amino acids, and then dividing that by the total number of amino acids and multiplying by 100.

By “specifically binds” or “has specificity to,” it is generally meant that an antibody binds to an epitope via its antigen-binding domain, and that the binding entails some complementarity between the antigen-binding domain and the epitope. ing to this definition, an antibody is said to “specifically bind” to an epitope when it binds to that epitope, via its antigen-binding domain more readily than it would bind to a random, unrelated epitope.

The term “specificity” is used herein to qualify the relative affinity by which a certain antibody binds to a certain epitope. For example, antibody “A” may be deemed to have a higher specificity for a given epitope than antibody “B,” or antibody “A” may be said to bind to epitope “C” with a higher specificity than it has for related epitope “D.” As used herein, the terms ” or “treatment” refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the progression of . Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease ssion, amelioration or palliation ofthe e state, and remission (whether partial or , whether detectable or undetectable. ment” can also mean prolonging al as ed to eXpected survival if not receiving ent. Those in need oftreatment include those already with the ion or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.

By “subject” or “individual” or “animal” or “patient” or “mammal,” is meant any subject, ularly a ian subject, for whom diagnosis, prognosis, or therapy is desired.

Mammalian subjects include , domestic animals, farm animals, and zoo, sport, or pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, , cows, and so on.

As used herein, phrases such as “to a patient in need of treatment” or “a subject in need oftreatment” includes subjects, such as mammalian subjects, that would benefit from D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] r Unmarked set by r administration of an antibody or composition of the present disclosure used, 6. g., for detection, for a stic procedure and/or for ent.

Anti-PD-LI dies The present disclosure es anti-PD-Ll antibodies with high affinity to the human PD-Ll protein. The tested antibodies exhibited potent binding and inhibitory activities and are useful for therapeutic and diagnostics uses.

The PD-Ll protein is a 40kDa type 1 transmembrane protein. Its extracellular portion s an N-terminal immunoglobulin V (IgV) domain (amino acids 19-127) and a C-terminal immunoglobulin C (IgC) domain (amino acids 133-225). PD-l and PD-Ll interact through the conserved front and side of their IgV domains, as do the IgV domains of antibodies and T cell ors. Not surprisingly, the current anti-PD-Ll antibodies all bind to the IgV domain which can disrupt the binding between PD-l and PD-Ll. It is therefore a surprising and uneXpected finding of the present disclosure that antibodies, such as many disclosed herein, that bind to the IgC domain of the PD-Ll protein can still effectively, and perhaps even more so, inhibit PD-Ll, leading to even fithher improved therapeutic s.

One embodiment of the present disclosure, therefore, provides an anti-PD-Ll antibody or nt thereof, which antibody or fragment thereof can specifically bind to an immunoglobulin C (Ig C) domain of a human Programmed death-ligand l (PD-Ll) protein. In some embodiments, the Ig C domain consists of amino acid residues 133-225.

In some embodiments, the dy or fragment thereof can bind to at least one of amino acid residues Yl34, K162, or N183 of the PD-Ll protein. In some embodiments, the antibody or fragment thereof can bind to at least two of amino acid residues Yl34, K162, or N183 of the PD-Ll protein. In some embodiments, the antibody or fragment thereof can bind to at least one of amino acid residues Yl34, K162, and N183 of the PD-Ll protein. In some embodiments, the antibody or fragment thereof does not bind to an immunoglobulin V (Ig V) domain of the PD-Ll protein, wherein the Ig V domain consists of amino acid residues 19-127.

In accordance with one ment ofthe present disclosure, provided is an dy that includes the heavy chain and light chain variable domains with the CDR regions as defined in SEQ ID NO: 1-6.

B [Annotation] wilksar None set by wilksar [Annotation] r ionNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar ation] r MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar Table 1. Sequences of the CDR regions Name Sequence SEQ ID NO: £DM§ l i CDR3 EFGKRYALDY .4 CDRl KA§QDVTPAVA _ <2.4 CDR3 QHYTTPLT 6 As demonstrated in the experimental examples, the antibodies that contained these CDR regions, r mouse, humanized or chimeric, had potent PD-Ll binding and inhibitory activities. Further computer modeling indicated that certain residues within the CDR can be d to retain or improve the property of the antibodies. Such residues are referred to as “hot spots” which are underlined in Table 1. In some embodiments, an anti-PD-Ll antibody of the present disclosure includes the VH and VL CDR as listed in Table l, with one, two or three fithher modifications. Such modifications can be addition, deletion or substation of amino acids.

In some embodiments, the modification is substitution at no more than one hot spot position from each ofthe CDRs. In some embodiments, the modification is substitution at one, two or three such hot spot positions. In one embodiment, the modification is substitution at one ofthe hot spot positions. Such substitutions, in some embodiments, are conservative substitutions.

A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, ing basic side chains (e. g., lysine, arginine, histidine), acidic side chains (e. g., aspartic acid, glutamic acid), uncharged polar side chains (e. g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e. g., e, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), ranched side chains (e. g., threonine, valine, cine) and aromatic side chains (e. g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a nonessential amino acid residue in an immunoglobulin polypeptide is preferably replaced with another amino acid residue from the same side chain family. In another embodiment, a string of amino acids can be replaced with a urally similar string that differs in order and/or composition of side chain family members.

D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar [Annotation] r None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar Non-limiting examples of conservative amino acid substitutions are provided in the table below, where a similarity score of 0 or higher indicates conservative substitution between the two amino acids.

Table 2. Amino Acid Similarity Matrix I ,_i I ,_i I—II—I IO'H Table 3. Conservative Amino Acid Substitutions For Amino Acid Substitution With D-Ala, Gly, Aib, B-Ala, L-Cys, D-Cys ne D-Arg, Lys, D-Lys, Orn D-Orn Asparagine D-Asn, Asp, D-Asp, Glu, D-Glu Gln, D-Gln Aspartic Acid D-Asp, D-Asn, Asn, Glu, D-Glu, Gln, D-Gln D-Cys, S-Me-Cys, Met, D-Met, Thr, D-Thr, L-Ser, D-Ser D-Glu, D-Asp, Asp, Asn, D-Asn, Gln, D-Gln Ala, D-Ala, Pro, D-Pro, Aib, fi-Ala D-Ile, Val, D-Val, Leu, D-Leu, Met, D-Met Leucine Val, D-Val, Met, D-Met, D-Ile, D-Leu, Ile [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar Lysine D-Lys, Arg, D-Arg, Orn, D-Orn Methromne D-Met, S-Me-Cys, Ile, D-Ile, Leu, D-Leu, Val, D-Val alanine D-Phe, Tyr, D-Tyr, His, D-His, Trp, D-Trp D-Ser, Thr, D-Thr, allo-Thr, L-Cys, D-Cys Threomne D-Thr, Ser, D-Ser, allo-Thr, Met, D-Met, Val, D-Val D-Tyr, Phe, D-Phe, His, D-His, Trp, D-Trp Valine D-Val, Leu, D-Leu, Ile, D-Ile, Met, D-Met Specific examples of CDRs with suitable substitutions are provided in SEQ ID NO: 61- 111 of Example 11. In some ments, ore, an dy of the present disclosure includes a VH CDRl of SEQ ID NO: 1 or any one of 61-67. In some embodiments, an antibody ofthe present disclosure includes a VH CDR2 of SEQ ID NO: 2 or any one of 68-77. In some ments, an antibody of the present disclosure includes a VH CDR3 of SEQ ID NO: 1 or any one of 78-90. In some embodiments, an antibody of the present disclosure includes a VL CDRl of SEQ ID NO: 4 or any one of 91-92. In some embodiments, an antibody of the present disclosure includes a VL CDR2 of SEQ ID NO: 5 or any one of 93-105. In some embodiments, an antibody ofthe present disclosure includes a VL CDR3 of SEQ ID NO: 6 or any one of 106- 1 10.

In some embodiments, an antibody or fragment thereof includes no more than one, no more than two, or no more than three of the above tutions. In some embodiments, the antibody or fragment thereof includes a VH CDRl of SEQ ID NO: 1 or any one of SEQ ID NO: 61-67, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, a VL CDRl of SEQ ID NO: 4, aVL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6.

In some ments, the antibody or fragment thereof includes a VH CDRl of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2 or any one of SEQ ID NO: 68-77, a VH CDR3 of SEQ ID NO: 3, aVL CDRl of SEQ ID NO: 4, aVL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6.

D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] r Unmarked set by wilksar ation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r In some ments, the antibody or fragment thereof includes a VH CDRl of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3 or any one of SEQ ID NO: 78-90, a VL CDRl of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6.

In some embodiments, the antibody or fragment thereof includes a VH CDRl of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, aVL CDRl of SEQ ID NO: 4 or any one of SEQ ID NO: 9l-92, a VL CDR2 of SEQ ID NO: 5, and aVL CDR3 of SEQ ID NO: 6.

In some embodiments, the antibody or fragment thereof includes a VH CDRl of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, aVL CDRl of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5 or any one of SEQ ID NO: , and a VL CDR3 of SEQ ID NO: 6.

In some embodiments, the antibody or fragment thereof includes a VH CDRl of SEQ ID NO: 1, a VH CDR2 of SEQ ID NO: 2, a VH CDR3 of SEQ ID NO: 3, aVL CDRl of SEQ ID NO: 4, a VL CDR2 of SEQ ID NO: 5, and a VL CDR3 of SEQ ID NO: 6 or any one of SEQ ID NO: 106-1 1 l.

Non-limiting examples ofVH are provided in SEQ ID NO: 7-26 and 113, out of which SEQ ID NO: 113 is the mouse VH, and SEQ ID NO: 7-26 are humanized ones. Further, among the humanized VH, SEQ ID NO: 9-15, 17-21 and 23-26 include one or more back-mutations to the mouse version. Likewise, non-limiting examples ofVL (VK) are provided in SEQ ID NO: 27-33. SEQ ID NO: 28 and 30 are the ally derived, CDR-grafted, humanized sequences as shown in the examples. SEQ ID NO: 29 and 3 1-33 are humanized VL with back-mutations.

The back-mutations are shown to be usefiil for retaining certain characteristics of the anti-PD-Ll antibodies. Accordingly, in some embodiments, the anti-PD-Ll antibodies of the present disclosure, in particular the human or humanized ones, include one or more of the back- mutations. In some embodiments, the VH back-mutation (i.e., ed amino acid at the specified position) is one or more selected from (a) Ser at position 44, (b) Ala at position 49, (c) Ala at on 53, (d) Ile at position 91, (e) Glu at position 1, (f) Val at position 37, (g) Thr at position 40 (h) Val at position 53, (i) Glu at position 54, (j) Asn at position 77, (k) Arg at D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by r [Annotation] r MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar position 94, and (l) Thr at position 108, according to Kabat numbering, and combinations thereof. In some embodiments, the back-mutations are selected from (a) Ser at on 44, (b) Ala at position 49, (c) Ala at position 53, and/or (d) Ile at on 91, according to Kabat numbering, and combinations thereof.

In some embodiments, the VL back-mutation is one or more selected from (a) Ser at position 22, (b) Gln at position 42, (c) Ser at position 43, (d) Asp at position 60, and (e) Thr at position 63, according to Kabat ing, and combinations thereof.

In some ments, the anti-PD-Ll antibody of the present disclosure includes a VH of SEQ ID NO: 7-26, a VL of SEQ ID NO: 27-33, or their respective biological equivalents. A biological equivalent of a VH or VL is a sequence that includes the designated amino acids while having an overall 80%, 85%, 90%, 95%, 98% or 99% sequence identity. A biological equivalent of SEQ ID NO: 20, for instance, can be a VH that has an overall 80%, 85%, 90%, 95%, 98% or 99% sequence identity to SEQ ID NO: 20 but retains the CDRs (SEQ ID NO: 1-6 or their variants), and optionally retains one or more, or all ofthe back-mutations. In one embodiment, the VH has the amino acid ce of SEQ ID NO: 20 and the VL has the amino acid ce of SEQ ID NO: 28.

It will also be understood by one of ordinary skill in the art that antibodies as disclosed herein may be modified such that they vary in amino acid sequence from the naturally occurring binding ptide from which they were derived. For example, a polypeptide or amino acid sequence derived from a designated n may be similar, 6. g., have a certain percent ty to the ng sequence, e.g., it may be 60%, 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99% identical to the starting sequence.

In certain embodiments, the antibody comprises an amino acid sequence or one or more moieties not normally associated with an antibody. Exemplary modifications are described in more detail below. For example, an antibody ofthe disclosure may comprise a flexible linker sequence, or may be modified to add a functional moiety (e.g., PEG, a drug, a toxin, or a label).

Antibodies, ts, or derivatives thereof of the disclosure include derivatives that are modified, i.e., by the covalent attachment of any type of le to the antibody such that covalent attachment does not prevent the antibody from binding to the epitope. For example, but D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar ation] wilksar None set by r [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar not by way of limitation, the antibodies can be modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, e to a cellular ligand or other protein, etc. Any ofnumerous chemical modifications may be carried out by known techniques, including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the antibodies may contain one or more non- cal amino acids.

In some embodiments, the antibodies may be conjugated to therapeutic agents, prodrugs, peptides, proteins, enzymes, viruses, lipids, biological response modifiers, ceutical , or PEG.

The antibodies may be conjugated or filSCd to a therapeutic agent, which may include detectable labels such as radioactive , an immunomodulator, a hormone, an enzyme, an oligonucleotide, a photoactive therapeutic or stic agent, a cytotoxic agent, which may be a drug or a toxin, an ultrasound enhancing agent, a non-radioactive label, a combination thereof and other such agents known in the art.

The antibodies can be ably labeled by ng it to a chemiluminescent compound. The presence of the chemiluminescent-tagged antigen-binding polypeptide is then determined by detecting the presence of luminescence that arises during the course of a al reaction. Examples of particularly USCfill chemiluminescent labeling compounds are luminol, inol, theromatic acridinium ester, imidazole, acridinium salt and oxalate ester.

The dies can also be detectably labeled using fluorescence emitting metals such as 152Eu, or others of the lanthanide series. These metals can be attached to the antibody using such metal chelating groups as diethylenetriaminepentacetic acid (DTPA) or ethylenediaminetetraacetic acid (EDTA). Techniques for conjugating s moieties to an antibody are well known, see, e.g., Arnon er al., “Monoclonal Antibodies For targeting Of Drugs In Cancer Therapy”, in Monoclonal Antibodies And Cancer Therapy, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. (1985), Hellstrom er al., “Antibodies For Drug Delivery”, in Controlled Drug Delivery (2nd Ed), Robinson et al., (eds.), Marcel Dekker, Inc., pp. 623- 53 (1987), Thorpe, ody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review”, in Monoclonal Antibodies '84: Biological And Clinical Applications, Pinchera er al. (eds.), pp.

D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar ionNone set by wilksar [Annotation] wilksar Unmarked set by wilksar 475-506 (1985), “Analysis, Results, And Future ctive Of The Therapeutic Use Of Radiolabeled dy In Cancer Therapy”, in Monoclonal Antibodies For Cancer Detection And Therapy, Baldwin et al. (eds.), Academic Press pp. 303-16 , and Thorpe er al., “The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates”, Immunol. Rev. (52: 119- 58 (1982)).

Bi-functional Molecules PD-L1 is an immune checkpoint molecule and is also atumor antigen. As atumor antigen targeting molecule, an antibody or antigen-binding fragment specific to PD-L1 can be combined with a second antigen-binding fragment specific to an immune cell to te a bispecific antibody.

In some embodiments, the immune cell is ed from the group consisting of a T cell, a B cell, a monocyte, a macrophage, a neutrophil, a dendritic cell, a phagocyte, a natural killer cell, an eosinophil, a basophil, and a mast cell. Molecules on the immune cell which can be targeted include, for example, CD3, CD16, CD19, CD28, and CD64. Other examples include PD-1, CTLA-4, LAG-3 (also known as CD223), CD28, CD122, 4-1BB (also known as CD137), TIM3, OX-40 or OX40L, CD40 or CD40L, LIGHT, ICOS/ICOSL, GITR/GITRL, TIGIT, CD27, VISTA, B7H3, B7H4, HEVM or BTLA (also known as CD272), killer-cell immunoglobulin-like receptors (KIRs), and CD47. Specific examples ofbispecificity include, without limitation, PD-Ll/PD-l, PD-L1/LAG3, PD-Ll/TIGIT, and PD-L1/CD47.

As an immune checkpoint inhibitor, an antibody or antigen-binding fragment specific to PD-L1 can be combined with a second antigen-binding fragment c to a tumor antigen to generate a ific dy. A “tumor antigen” is an antigenic substance produced in tumor cells, i.e., it triggers an immune se in the host. Tumor antigens are useful in identifying tumor cells and are potential candidates for use in cancer therapy. Normal proteins in the body are not antigenic. Certain proteins, however, are produced or overexpressed during tumorigenesis and thus appear “foreign” to the body. This may include normal proteins that are well sequestered from the immune system, proteins that are normally produced in extremely small ties, ns that are normally produced only in n stages of development, or ns whose structure is modified due to mutation.

D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar An abundance oftumor ns are known in the art and new tumor antigens can be readily identified by screening. miting examples oftumor antigens include EGFR, Her2, EpCAM, CD20, CD30, CD33, CD47, CD52, CD133, CD73, CEA, gpA33, Mucins, TAG-72, CIX, PSMA, folate-binding n, GD2, GD3, GM2, VEGF, VEGFR, Integrin, ocVB3, OLSBl, ERBBZ, ERBB3, MET, IGFlR, EPHA3, TRAILRl, TRAILRZ, RANKL, FAP and in.

In some aspects, the monovalent unit has specificity to a protein that is overexpressed on a tumor cell as compared to a corresponding non-tumor cell. A “corresponding non-tumor cell” as used here, refers to a non-tumor cell that is of the same cell type as the origin of the tumor cell. It is noted that such proteins are not arily different from tumor antigens. Non-limiting examples include carcinoembryonic antigen (CEA), which is overexpressed in most colon, , breast, lung, pancreas and intestinal tract carcinomas, lin ors (HER-2, new or c-erbB-Z), which is frequently overexpressed in breast, ovarian, colon, lung, te and cervical s, epidermal growth factor receptor (EGFR), which is highly expressed in a range of solid tumors including those of the breast, head and neck, non-small cell lung and prostate, asialoglycoprotein receptor, transferrin receptor, serpin enzyme complex receptor, which is expressed on hepatocytes, fibroblast growth factor receptor (FGFR), which is overexpressed on pancreatic ductal adenocarcinoma cells, vascular endothelial growth factor or (VEGFR), for anti-angiogenesis gene therapy, folate receptor, which is selectively overexpressed in 90% of nonmucinous ovarian carcinomas, cell surface glycocalyx, carbohydrate receptors, and polymeric immunoglobulin receptor, which is useful for gene delivery to respiratory epithelial cells and attractive for treatment of lung diseases such as Cystic Fibrosis. Non-limiting examples of bispecificity in this t include PD-Ll/EGFR, PD-Ll/Her2, PD-Ll/CD33, PD- Ll/CD133, CEA and PD-Ll/VEGF.

Different format of bispecific antibodies are also provided. In some embodiments, each ofthe anti-PD-Ll fragment and the second fragment each is independently ed from a Fab fragment, a single-chain variable fragment (scFv), or a single-domain antibody. In some embodiments, the bispecific antibody fithher includes a Fc fragment.

Bifiinctional molecules that include not just antibody or antigen binding fragment are also provided. As a tumor antigen targeting molecule, an antibody or antigen-binding fragment specific to PD-Ll, such as those described here, can be combined with an immune cytokine or D [Annotation] wilksar None set by r [Annotation] wilksar ionNone set by wilksar [Annotation] wilksar Unmarked set by r [Annotation] wilksar None set by wilksar [Annotation] r MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar ligand optionally through a peptide . The linked immune cytokines or ligands include, but not limited to, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, GM-CSF, TNF-oc, CD40L, OX40L, CD27L, CD30L, 4-1BBL, LIGHT and GITRL. Such bi-fiJnctional molecules can combine the immune checkpoint blocking effect with tumor site local immune modulation.

Polynucleotides Encoding the Antibodies and Methods ofPreparing the Antibodies The present disclosure also provides isolated polynucleotides or nucleic acid molecules (e.g., SEQ ID NO: 34-60, 112, and 114) ng the antibodies, variants or derivatives thereof ofthe sure. The polynucleotides ofthe present disclosure may encode the entire heavy and light chain variable regions of the antigen-binding polypeptides, variants or derivatives thereof on the same polynucleotide le or on separate polynucleotide molecules.

Additionally, the polynucleotides of the present disclosure may encode portions of the heavy and light chain variable regions of the antigen-binding polypeptides, variants or derivatives thereof on the same polynucleotide molecule or on separate polynucleotide molecules.

Methods of making antibodies are well known in the art and described herein. In certain embodiments, both the variable and constant s of the antigen-binding polypeptides of the present disclosure are fiilly human. Fully human antibodies can be made using techniques described in the art and as described herein. For e, fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in se to antigenic challenge, but whose endogenous loci have been disabled. Exemplary techniques that can be used to make such antibodies are described in US. patents: 6,150,584, 592, 6,420,140 which are incorporated by reference in their entireties.

In n embodiments, the prepared antibodies will not elicit a deleterious immune response in the animal to be treated, e.g., in a human. In one embodiment, antigen-binding polypeptides, variants, or tives thereof of the disclosure are modified to reduce their immunogenicity using art- recognized techniques. For example, antibodies can be humanized, primatized, deimmunized, or chimeric antibodies can be made. These types of antibodies are derived from a man antibody, typically a murine or primate antibody, that retains or substantially retains the antigen-binding properties of the parent antibody, but which is less immunogenic in humans. This may be achieved by s methods, including (a) grafting the D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar ation] wilksar None set by wilksar [Annotation] r MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar entire non-human variable domains onto human constant regions to te chimeric antibodies; (b) grafting at least a part of one or more of the non-human complementarity determining regions (CDRs) into a human framework and constant regions with or without retention of critical framework residues; or (c) transplanting the entire non-human variable domains, but “cloaking” them with a human-like section by replacement of surface residues.

Such methods are sed in Morrison et al.; Proc. Natl. Acad. Sci. USA 57:6851-6855 (1984); Morrison er al.; Adv. Immunol. 44:65-92 (1988); Verhoeyen er al., e 239: 1534-1536 (1988); Padlan; Molec. Immun. -498 (1991); Padlan; Molec. Immun. 31: 7 (1994); and US. Pat. Nos.: 5,585;089; 5,693;761; 5,693;762; and 6,190;370; all ofwhich are hereby incorporated by reference in their entirety.

De-immunization can also be used to decrease the genicity of an antibody. As used herein; the term “de-immunization” es alteration of an dy to modify T-cell epitopes (see, e.g.; ational Application Publication Nos.: WO/9852976 A1 and WO/0034317 A2). For example; variable heavy chain and variable light chain sequences from the starting antibody are ed and a human T-cell epitope “map” from each V region showing the location of epitopes in relation to complementarity-determining regions (CDRs) and other key residues within the sequence is d. Individual T-cell epitopes from the T-cell epitope map are analyzed in order to identify alternative amino acid substitutions with a low risk of altering activity of the final antibody. A range of alternative variable heavy and variable light sequences are designed comprising combinations of amino acid substitutions and these sequences are subsequently incorporated into a range of binding polypeptides. Typically; between 12 and 24 variant antibodies are generated and tested for binding and/or fill’lCthl’l.

Complete heavy and light chain genes comprising modified variable and human constant regions are then cloned into eXpression vectors and the subsequent plasmids introduced into cell lines for the production of whole antibody. The dies are then compared in appropriate biochemical and biological assays; and the optimal variant is fied.

The binding specificity of antigen-binding polypeptides ofthe present disclosure can be determined by in vitro assays such as immunoprecipitation; radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA).

D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar Alternatively, techniques described for the tion of single-chain units (US. Pat.

No. 4,694,778, Bird, Science 242:423-442 (1988), Huston et al., Proc. Natl. Acad. Sci. USA 55:5879- 5883 (1988), and Ward et al., Nature 4-554 (1989)) can be adapted to produce single-chain units ofthe present disclosure. Single-chain units are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single-chain filSlOl’l peptide. Techniques for the ly of fiinctional Fv fragments in E. coli may also be used (Skerra et al., Science 242: 1038-1041 (1988)).

Examples oftechniques which can be used to produce -chain Fvs (scFvs) and antibodies include those described in US. Pat. Nos. 4,946,778 and 5,258,498, Huston et al., Methods in Enzymology 203:46-88 (1991), Shu et al., Proc. Natl. Sci. USA 90: 1995-1999 (1993), and Skerra et al., Science 240: 1038-1040 (1988). For some uses, including in viva use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A ic antibody is a molecule in which different portions ofthe antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. s for producing ic antibodies are known in the art. See, e. g., Morrison, Science 229: 1202 (1985), Oi et al., BioTechniques 4:214 (1986), Gillies et al., J. l. s 125: 191-202 (1989), US. Pat. Nos. 5,807,715, 4,816,567, and 4,816397, which are incorporated herein by reference in their ties.

Humanized antibodies are antibody molecules derived from a non-human species dy that bind the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and framework regions from a human immunoglobulin molecule. Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve, n- binding. These framework substitutions are fied by methods well known in the art, e. g., by modeling ofthe ctions of the CDR and framework residues to fy framework residues important for antigen-binding and sequence comparison to identify unusual framework residues at particular positions. (See, e. g., Queen et al., US. Pat. No. 5,585,089, Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety oftechniques known in the art including, for example, CDR-grafting (EP 239,400, PCT ation WO 91/09967, US. Pat. Nos. 5,225,539, D [Annotation] wilksar None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar ,530,101, and 5,585,089), veneering or resurfacing (EP 592,106, EP 519,596, Padlan, Molecular logy 28(4/5):489-498 (1991), Studnicka et al., Protein Engineering 7(6):805- 814 (1994), Roguska. et al, Proc. Natl. Sci. USA 91:969-973 (1994)), and chain shuffling (US.

Pat. No. 5,565,332, which is incorporated by reference in its entirety).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a y of methods known in the art ing phage display methods using antibody libraries derived from human immunoglobulin ces. See also, US. Pat. Nos. 4,444,887 and 4,716,111, and PCT publications W0 45, W0 98/50433, W0 98/24893, W0 98/16654, W0 96, W0 35, and W0 9 1/ 10741, each of which is incorporated herein by reference in its entirety.

Human antibodies can also be produced using enic mice which are incapable of expressing functional endogenous globulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the human variable region, constant , and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes. The mouse heavy and light chain immunoglobulin genes may be rendered non-fimctional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous dy production. The modified embryonic stem cells are expanded and microinjected into cysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring that s human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e. g., all or a n of a d target polypeptide. Monoclonal antibodies directed against the antigen can be obtained from the immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B-cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically usefiil IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human antibodies, see Lonberg and Huszar Int. Rev. Immunol. 73:65-93 (1995). For a detailed discussion ofthis technology for producing human antibodies and human monoclonal antibodies and protocols for producing D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] r MigrationNone set by r [Annotation] wilksar ed set by wilksar such antibodies, see, e.g., PCT publications WO 98/24893, WO 96/34096, WO 96/33735, US.

Pat. Nos. 5,413,923, 5,625,126, 5,633,425, 5,569,825, 5,661,016, 806, 5,814,318, and ,939,598, which are orated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, Calif.) and GenPharm (San Jose, Calif.) can be engaged to provide human antibodies directed t a selected antigen using technology similar to that described above.

Completely human antibodies which recognize a selected e can also be generated using a technique referred to as “guided selection.” In this approach a selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/Technology 72:899-903 (1988). See also, US. Patent No. 5,565,332, which is incorporated by reference in its entirety.) In another embodiment, DNA encoding desired monoclonal antibodies may be readily isolated and sequenced using conventional procedures (6. g., by using ucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The isolated and subcloned hybridoma cells serve as a preferred source of such DNA. Once isolated, the DNA may be placed into expression s, which are then transfected into prokaryotic or eukaryotic host cells such as E. coli cells, simian COS cells, Chinese Hamster Ovary (CHO) cells or a cells that do not otherwise e immunoglobulins. More particularly, the isolated DNA (which may be synthetic as described herein) may be used to clone constant and variable region sequences for the manufacture antibodies as described in Newman et al., US. Pat. No. 5,658,570, filed January 25, 1995, which is incorporated by reference herein. Essentially, this entails extraction of RNA from the selected cells, conversion to cDNA, and amplification by PCR using Ig specific primers.

Suitable primers for this purpose are also described in US. Pat. No. 5,658,570. As will be discussed in more detail below, transformed cells sing the desired antibody may be grown up in vely large quantities to e clinical and commercial supplies of the globulin.

Additionally, using routine recombinant DNA techniques, one or more ofthe CDRs of the antigen-binding polypeptides of the present sure, may be inserted within framework s, 6. g., into human framework regions to humanize a non-human antibody. The D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278:457-479 (1998) for a listing of human framework s). Preferably, the polynucleotide generated by the combination ofthe framework regions and CDRs encodes an antibody that specifically binds to at least one epitope of a desired polypeptide, e. g., LIGHT. Preferably, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the cleotide are encompassed by the present sure and within the skill ofthe art.

In addition, techniques developed for the production of “chimeric antibodies” son et al., Proc. Natl. Acad. Sci. USA:851-855 (1984), Neuberger et al., Nature 372:604-608 (1984), Takeda et al., Nature 314:452-454 (1985)) by splicing genes from a mouse antibody molecule, of appropriate antigen specificity, together with genes from a human antibody molecule of appropriate biological activity can be used. As used herein, a chimeric antibody is a molecule in which ent portions are derived from different animal species, such as those having a variable region d from a murine monoclonal antibody and a human immunoglobulin constant .

Yet r highly efficient means for generating recombinant antibodies is disclosed by Newman, Biotechnology 10: 1455-1460 (1992). Specifically, this technique results in the generation of primatized antibodies that contain monkey variable s and human constant ces. This reference is incorporated by reference in its entirety herein. Moreover, this technique is also described in commonly ed US. Pat. Nos. 5,658,570, 5,693,780 and ,756,096 each of which is incorporated herein by nce.

Alternatively, dy-producing cell lines may be ed and cultured using ques well known to the skilled artisan. Such techniques are described in a variety of tory manuals and primary publications. In this respect, techniques le for use in the disclosure as described below are described in Current Protocols in Immunology, Coligan et al., D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar Eds, Green Publishing Associates and Wiley-Interscience, John Wiley and Sons, New York (1991) which is herein incorporated by reference in its entirety, ing supplements.

Additionally, rd techniques known to those of skill in the art can be used to introduce mutations in the nucleotide sequence encoding an antibody of the present disclosure, including, but not limited to, site-directed nesis and diated mutagenesis which result in amino acid substitutions. Preferably, the variants (including derivatives) encode less than 50 amino acid substitutions, less than 40 amino acid subsitutions, less than 30 amino acid substitutions, less than 25 amino acid substitutions, less than 20 amino acid substitutions, less than 15 amino acid substitutions, less than 10 amino acid substitutions, less than 5 amino acid tutions, less than 4 amino acid substitutions, less than 3 amino acid tutions, or less than 2 amino acid substitutions relative to the reference le heavy chain region, CDR—Hl, CDR-H2, CDR-H3, variable light chain region, CDR-Ll, CDR-L2, or CDR-L3. Alternatively, mutations can be introduced randomly along all or part ofthe coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for biological ty to fy mutants that retain activity.

Cancer ent As described herein, the dies, variants or derivatives of the present disclosure may be used in certain treatment and diagnostic methods.

The present disclosure is fithher directed to antibody-based therapies which involve administering the antibodies of the disclosure to a patient such as an animal, a mammal, and a human for treating one or more ofthe disorders or conditions described herein. Therapeutic compounds of the disclosure e, but are not limited to, antibodies ofthe disclosure ding variants and derivatives thereof as described herein) and nucleic acids or polynucleotides encoding antibodies ofthe disclosure (including variants and derivatives thereof as described herein).

The antibodies ofthe disclosure can also be used to treat or inhibit cancer. PD-Ll can be overeXpressed in tumor cells. Tumor-derived PD-Ll can bind to PD-l on immune cells thereby limiting antitumor T-cell immunity. Results with small molecule inhibitors, or monoclonal antibodies targeting PD-Ll in murine tumor , indicate that targeted PD-Ll therapy is an D ation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r important alternative and realistic approach to effective control of tumor growth. As demonstrated in the experimental examples, the anti-PD-Ll dies activated the adaptive immune response machinery, which can lead to improved survival in cancer patients.

Accordingly, in some embodiments, provided are s for treating a cancer in a patient in need thereof. The method, in one ment, entails administering to the patient an effective amount of an antibody ofthe present disclosure. In some embodiments, at least one of the cancer cells (e.g., stromal cells) in the patient expresses, over-express, or is induced to express PD-Ll. Induction of PD-Ll expression, for ce, can be done by administration of a tumor vaccine or radiotherapy.

Tumors that express the PD-Ll protein include those of bladder cancer, non-small cell lung cancer, renal cancer, breast cancer, al cancer, colorectal cancer, head and neck , squamous cell cancer, Merkel cell carcinoma, gastrointestinal cancer, stomach cancer, oesophageal , ovarian cancer, renal cancer, and small cell lung cancer. Accordingly, the presently disclosed antibodies can be used for treating any one or more such s.

Cellular therapies, such as chimeric antigen receptor (CAR) T-cell therapies, are also provided in the present disclosure. A suitable cell can be used, that is put in contact with an anti- PD-Ll antibody of the t disclosure (or alternatively engineered to express an anti-PD-Ll antibody of the present disclosure). Upon such contact or engineering, the cell can then be introduced to a cancer patient in need of a ent. The cancer patient may have a cancer of any of the types as disclosed herein. The cell (e.g., T cell) can be, for instance, a tumor- infiltrating T lymphocyte, a CD4+ T cell, a CD8+ T cell, or the combination thereof, without limitation.

In some embodiments, the cell was isolated from the cancer patient him- or lf. In some embodiments, the cell was provided by a donor or from a cell bank. When the cell is ed from the cancer patient, undesired immune reactions can be minimized.

Additional diseases or conditions associated with increased cell survival, that may be treated, ted, diagnosed and/or prognosed with the antibodies or variants, or derivatives f ofthe disclosure include, but are not d to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e. g., acute D [Annotation] wilksar None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar lymphocytic ia, acute myelocytic leukemia (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e. g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., n's disease and non-Hodgkin's disease), multiple a, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited to, sarcomas and carcinomas such as rcoma, myxosarcoma, liposarcoma, osarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyo sarcoma, colon carcinoma, pancreatic cancer, breast cancer, thyroid cancer, endometrial cancer, ma, prostate , ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, ary adenocarcinomas, cystadenocarcinoma, medullary oma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung oma, bladder carcinoma, epithelial carcinoma, , astrocytoma, oblastoma, craniopharyngioma, ependymoma, pinealoma, ioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma and retinoblastoma.

Combination Therapies In a filI'tl’lCl‘ embodiment, the compositions of the disclosure are administered in combination with an antineoplastic agent, an antiviral agent, cterial or antibiotic agent or antifungal agents. Any of these agents known in the art may be administered in the itions of the current disclosure.

In another embodiment, compositions of the disclosure are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the compositions ofthe disclosure include, but are not limited to, antibiotic derivatives (6. g., doxorubicin, bleomycin, daunorubicin, and dactinomycin), antiestrogens (e. g., tamoxifen), antimetabolites (e.g., fluorouracil, 5-FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, topurine, and 6-thioguanine), cytotoxic agents (e.g., carmustine, BCNU, ine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by r [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r procarbazine, mitomycin, busulfan, cis-platin, and Vincristine sulfate); hormones (e. g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone), en d derivatives (e.g., mephalen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa), steroids and combinations (6. g., bethamethasone sodium phosphate); and others (6. g., dicarbazine, ginase, mitotane, Vincristine e, Vinblastine sulfate, and etoposide).

In an additional ment, the compositions of the disclosure are administered in combination with cytokines. Cytokines that may be administered with the compositions of the disclosure include, but are not d to, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12, IL-l3, IL-15, anti-CD40, CD40L, and TNF-oc.

In additional embodiments, the compositions ofthe disclosure are administered in combination with other eutic or prophylactic regimens, such as, for example, radiation therapy.

Combination therapies are also provided, which includes the use of one or more ofthe D-Ll antibody ofthe present sure along with a second anticancer (chemotherapeutic) agent. Chemotherapeutic agents may be categorized by their mechanism of action into, for e, the following groups: - anti-metabolites/anti-cancer agents such as pyrimidine analogs floxuridine, capecitabine, and cytarabine, - purine analogs, folate antagonists, and d inhibitors, - antiproliferative/antimitotic agents including natural products such as Vinca alkaloid (Vinblastine, Vincristine) and microtubule such as taxane (paclitaxel, docetaxel), Vinblastin, nocodazole, epothilones, Vinorelbine (NAVELBINE®), and ophyllotoxins (etoposide, teniposide), - DNA damaging agents such as actinomycin, amsacrine, busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide (CYTOXAN®), dactinomycin, daunorubicin, doxorubicin, epirubicin, iphosphamide, melphalan, merchlorethamine, mitomycin, D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar ntrone, nitrosourea, procarbazine, taxol, taxotere, teniposide, etoposide, and triethylenethiophosphoramide, - antibiotics such as omycin, daunorubicin, doxorubicin, idarubicin, anthracyclines, mitoxantrone, bleomycins, ycin (mithramycin), and mitomycin, - enzymes such as raginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine, - antiplatelet agents; - antiproliferative/antimitotic alkylating agents such as nitrogen mustards cyclophosphamide and analogs (melphalan, chlorambucil, hexamethylmelamine, and thiotepa), alkyl nitrosoureas (carmustine) and analogs, streptozocin, and triazenes bazine), - antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate), - um coordination complexes (cisplatin, oxiloplatinim, and carboplatin), procarbazine, hydroxyurea, mitotane, and aminoglutethimide, - hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, and nilutamide), and aromatase inhibitors (letrozole and anastrozole), - anticoagulants such as n, synthetic heparin salts, and other inhibitors of in, - fibrinolytic agents such as tissue plasminogen activator, streptokinase, urokinase, aspirin, dipyridamole, idine, and clopidogrel, - antimigratory agents, - antisecretory agents (breveldin), - immunosuppressives tacrolimus, sirolimus, azathioprine, and mycophenolate, - compounds 70, genistein) and growth factor inhibitors (vascular elial growth factor inhibitors and fibroblast growth factor inhibitors), - angiotensin receptor rs, nitric oxide donors, - anti-sense oligonucleotides, - antibodies such as trastuzumab and mab, - cell cycle inhibitors and differentiation inducers such as tretinoin, D ation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar - inhibitors, topoisomerase inhibitors (doxorubicin, daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin, irinotecan, mitoxantrone, topotecan, and irinotecan), and corticosteroids sone, thasone, hydrocortisone, methylprednisolone, prednisone, and prednisolone), - growth factor signal uction kinase inhibitors; - ction inducers; - toxins such as Cholera toxin, ricin, Pseudomonas exotoxin, Bordetella pertussis ate cyclase toxin, diphtheria toxin, and caspase activators, - and chromatin.

Further examples of chemotherapeutic agents e: - alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN®), - alkyl sulfonates such as busulfan, improsulfan, and piposulfan, - aziridines such as benzodopa, carboquone, meturedopa, and uredopa, - emylerumines and memylamelamines including alfretamine, triemylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide, and trimemylolomelamine, - acetogenins, especially bullatacin and bullatacinone, - a camptothecin, including synthetic analog topotecan, - bryostatin, - callystatin, - CC-1065, including its adozelesin, carzelesin, and bizelesin tic analogs, - cryptophycins, particularly cryptophycin l and cryptophycin 8, - dolastatin, - duocarmycin, including the tic analogs KW-2189 and CBI-TMI, - eleutherobin, - pancratistatin, - a sarcodictyin, - spongistatin, D [Annotation] wilksar None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar - nitrogen ds such as chlorambucil, chlomaphazine, cyclophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, and uracil mustard; - nitrosoureas such as carmustine, chlorozotocin, foremustine, lomustine, nimustine, and ranimustine, - antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammaII and calicheamicin , dynemicin including dynemicin A, bisphosphonates such as clodronate, an esperamicin, neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromomophores, aclacinomycins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazooxo-L-norleucine, doxorubicin ding morpholino- doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin, and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, ycin, rodorubicin, onigrin, streptozocin, tubercidin, ubenimeX, zinostatin, and zorubicin, - anti-metabolites such as methotrexate and ouracil (5 -FU), - folic acid analogs such as demopterin, methotrexate, pteropterin, and trimetrexate, - purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, and thioguanine, - pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofiJr, cytarabine, dideoxyuridine, doxifluridine, enocitabine, and dine, - androgens such as calusterone, dromostanolone nate, epitiostanol, mepitiostane, and testolactone, - anti-adrenals such as lutethimide, mitotane, and trilostane, - folic acid replinishers such as ic acid, - trichothecenes, especially T-2 toxin, verracurin A, roridin A, and ine, - taxoids such as paclitaxel (TAXOL®) and docetaxel (TAXOTERE®), - platinum s such as cisplatin and carboplatin, D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar - tone; aldophosphamide ide; aminolevulinic acid; eniluracil; amsacrine; hestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformthine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; leucovorin; lonidamine; maytansinoids such as sine and tocins; mitoguazone; mitoxantrone; mopidamol; rine; pentostatin; phenamet; pirarubicin; losoxantrone; fluoropyrimidine; folinic acid; podophyllinic acid; 2—ethylhydrazide; procarbazine; polysaccharide-K (PSK); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2';2"- tricUorotriemylamine; urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside C"); cyclophosphamide; thiopeta; chlorambucil; gemcitabine (GEMZAR®); 6-thioguanine; mercaptopurine; methotrexate; vinblastine; platinum; etoposide (VP- 1 6); ifosfamide; mitroxantrone; stine; vinorelbine (NAVELBINE®); novantrone; teniposide; edatrexate; ycin; aminopterin; xeoloda; ibandronate; CPT-l l; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DFMO); retinoids such as retinoic acid; capecitabine; FOLFIRI (fluorouracil; leucovorin; and ecan); - and pharmaceutically acceptable salts; acids; or derivatives of any ofthe above.

Also included in the ion of therapeutic agent” are anti-hormonal agents such as anti-estrogens and selective estrogen receptor modulators (SERMs); inhibitors of the enzyme aromatase; anti-androgens; and pharmaceutically acceptable salts; acids or derivatives of any of the above that act to regulate or inhibit hormone action on tumors. es of anti-estrogens and SERMs include; for example; tamoxifen (including NOLVADEXTM); raloxifene; droloxifene; 4-hydroxytamoxifen; trioxifene; ene; LYl 17018; onapristone; and fene (FARESTON®).

Inhibitors ofthe enzyme aromatase regulate estrogen tion in the adrenal glands.

Examples include 4(5)-imidazoles; aminoglutethimide; megestrol acetate (MEGACE®); exemestane; formestane; ole; le (RIVISOR®); letrozole (FEMARA®); and anastrozole (ARIMIDEX®).

Examples of ndrogens include flutamide; nilutamide; bicalutamide; leuprohde; and goserelin.

D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] wilksar Unmarked set by r Examples of chemotherapeutic agents also include anti-angiogenic agents including, but are not limited to, retinoid acid and derivatives thereof, 2-methoxyestradiol, TATIN®, ENDOSTATIN®, suramin, squalamine, tissue inhibitor of metalloproteinase-1, tissue inhibitor of metalloproteinase-2, plasminogen activator inhibitor-1, plasminogen activator inbibitor-2, cartilage-derived inhibitor, paclitaxel (nab-paclitaxel), platelet factor 4, protamine sulphate (clupeine), ted chitin derivatives (prepared from queen crab shells), sulphated polysaccharide peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism including proline analogs ((l-azetidinecarboxylic acid ), cishydroxyproline, d,I-3,4- dehydroproline, thiaproline, a,ot'—dipyridyl, beta-aminopropionitrile fiimarate, 4-propyl(4- pyridinyl)-2(3h)-oxazolone, methotrexate, mitoxantrone, heparin, interferons, 2 lobulin- serum, n inhibitor of metalloproteinase-3 (ChIMP-3), chymostatin, beta-cyclodextrin tetradecasulfate, ycin, fiJmagillin, gold sodium thiomalate, d-penicillamine, beta anticollagenase-serum, 2-antiplasmin, bisantrene, lobenzarit disodium, n carboxyphenylchloroanthronilic acid disodium or “CCA”, thalidomide, angiostatic steroid, carboxy aminoimidazole, and metalloproteinase inhibitors such as BB-94. Other anti- angiogenesis agents include antibodies, ably monoclonal dies against these angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF, and Ang-l/Ang-2.

Examples of chemotherapeutic agents also include anti-fibrotic agents including, but are not limited to, the compounds such as beta-aminoproprionitrile (BAPN), as well as the compounds disclosed in US. Patent No.: 4,965,288 eyman, et al.) relating to tors of lysyl oxidase and their use in the ent of diseases and conditions associated with the abnormal deposition of collagen and US. Patent No.: 4,997,854 (Kagan et al.) relating to compounds which inhibit LOX for the treatment of various pathological fibrotic states, which are herein incorporated by reference. Further exemplary inhibitors are bed in US. Patent No.: 4,943,593 (Palfreyman et al.) relating to compounds such as 2-isobutylfluoro-, chloro-, or bromo-allylamine, US. Patent Nos.: 5,021,456 (Palfreyman et al.), 5,059,714 (Palfreyman et al.), 764 (Mccarthy er al.), 5,182,297 (Palfreyman et al.), 5,252,608 (Palfreyman er al.) D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar relating to 2-(l-naphthyloxymemyl)fluoroallylamine, and US. Pub. No.: 2004/0248871 (Farjanel et al.), which are herein incorporated by reference.

Exemplary anti-fibrotic agents also include the primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce, after binding with the carbonyl, a product ized by resonance, such as the following y amines: emylenemamine, hydrazine, phenylhydrazine, and their derivatives, semicarbazide and urea derivatives, itriles such as BAPN or 2-nitroethylamine, unsaturated or saturated haloamines such as 2—bromo-ethylamine, roethylamine, 2- trifluoroethylamine, 3-bromopropylamine, and p-halobenzylamines, and selenohomocysteine lactone.

Other anti-fibrotic agents are copper chelating agents penetrating or not penetrating the cells. ary compounds include indirect inhibitors which block the aldehyde tives originating from the oxidative deamination of the lysyl and hydroxylysyl residues by the lysyl oxidases. Examples include the thiolamines, particularly cillamine, and its analogs such as 2—aminomercapto-5 -methylhexanoic acid, Damino-3 -methyl((2- acetamidoethyl)dithio)butanoic acid, pamino-3 -methyl((2-aminoethyl)dithio)butanoic acid, sodium((p-l-dimethylaminocarboxyethyl)dithio)butane sulphurate, 2- acetamidoethylacetamidoethanethiol sulphanate, and sodiummercaptobutanesulphinate rate.

Examples of chemotherapeutic agents also include immunotherapeutic agents including and are not limited to therapeutic antibodies suitable for treating ts. Some examples of therapeutic antibodies include simtuzumab, abagovomab, adecatumumab, afiituzumab, alemtuzumab, mab, amatuximab, omab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, mumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab, ensituximab, ertumaxomab, etaracizumab, farletuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, ganitumab, gemtuzumab, uximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, ximab, inotuzumab, D [Annotation] wilksar None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar intetumumab, ipilimumab, umab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab, namatumab, naptumomab, necitumumab, , nimotuzumab, momab, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, mumab, parsatuzumab, patritumab, pemtumomab, pertuzumab, pintumomab, pritumumab, momab, umab, rilotumumab, rituximab, robatumumab, satumomab, sibrotuzumab, siltuximab, solitomab, tacatuzumab, taplitumomab, tenatumomab, teprotumumab, zumab, tositumomab, zumab, tucotuzumab, ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, CC49, and 3F8. Rituximab can be used for treating indolent B-cell cancers, including al-zone lymphoma, WM, CLL and small lymphocytic lymphoma. A combination of Rituximab and chemotherapy agents is especially effective.

The exemplified therapeutic antibodies may be fithher labeled or ed with a radioisotope particle such as indium-l l l, yttrium-90, or iodine-131.

In a one embodiment, the additional eutic agent is a nitrogen mustard alkylating agent. Nonlimiting es of nitrogen mustard alkylating agents include chlorambucil.

In one embodiment, the compounds and compositions described herein may be used or combined with one or more onal therapeutic agents. The one or more therapeutic agents include, but are not limited to, an inhibitor of Abl, activated CDC kinase (ACK), ine A2B receptor (A2B), apoptosis signal-regulating kinase (ASK), Auroa kinase, Bruton’s tyrosine kinase (BTK), BET-bromodomain (BRD) such as BRD4, c-Kit, c-Met, CDK-activating kinase (CAK), calmodulin-dependent protein kinase (CaMK), cyclin-dependent kinase (CDK), casein kinase (CK), discoidin domain receptor (DDR), mal growth factor receptors (EGFR), focal adhesion kinase (FAK), Flt-3, FYN, glycogen synthase kinase (GSK), HCK, histone deacetylase (HDAC), IKK such as IKKBS, isocitrate dehydrogenase (IDH) such as IDHl, Janus kinase (JAK), KDR, lymphocyte-specific protein tyrosine kinase (LCK), lysyl e protein, lysyl oxidase-like protein (LOXL), LYN, matrix metalloprotease (MMP), MEK, mitogen- activated protein kinase (MAPK), NEK9, NPM-ALK, p38 kinase, platelet-derived growth factor (PDGF), phosphorylase kinase (PK), polo-like kinase (PLK), phosphatidylinositol 3-kinase (PI3K), protein kinase (PK) such as protein kinase A, B, and/or C, PYK, spleen tyrosine kinase (SYK), serine/threonine kinase TPL2, serine/threonine kinase STK, signal transduction and D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] r Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar transcription (STAT), SRC, serine/threonine-protein kinase (TBK) such as TBKl, TIE, tyrosine kinase (TK), vascular endothelial growth factor receptor (VEGFR), YES, or any combination thereof.

ASK inhibitors include ASKl tors. Examples of ASK1 inhibitors include, but are not limited to, those described in W0 2011/008709 (Gilead Sciences) and W0 2013/112741 (Gilead Sciences).

Examples ofBTK inhibitors include, but are not limited to, ibrutinib, HM71224, 0N0- 4059, and CC-292.

DDR inhibitors include inhibitors of DDR1 and/or DDR2. Examples of DDR inhibitors include, but are not limited to, those disclosed in W0 2014/047624 (Gilead Sciences), US 2009/0142345 (Takeda Pharmaceutical), US 2011/0287011 (0ncomed ceuticals), W0 2013/027802 i Pharmaceutical), and W0 2013/034933 (Imperial tions).

Examples ofHDAC inhibitors include, but are not limited to, ostat and panobinostat.

JAK inhibitors inhibit JAKl, JAK2, and/or JAK3. Examples of JAK tors include, but are not limited to, filgotinib, ruxolitinib, fedratinib, tinib, baricitinib, lestaurtinib, pacritinib, XL019, 0, INCB039110, LY2784544, BMS911543, and NS018.

LOXL inhibitors include inhibitors of LOXL1, LOXL2, LOXL3, LOXL4, and/or LOXL5. Examples ofLOXL inhibitors include, but are not limited to, the antibodies bed in W0 2009/017833 (Arresto Biosciences).

Examples ofLOXL2 inhibitors include, but are not limited to, the antibodies described in W0 2009/017833 (Arresto Biosciences), W0 2009/035791 (Arresto Biosciences), and W0 2011/097513 (Gilead Biologics).

MMP inhibitors include inhibitors ofMMPl h 10. Examples of MMP9 inhibitors include, but are not limited to, marimastat (BB-2516), stat (Ro 5), and those described in W0 2012/027721 (Gilead Biologics).

D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar PI3K inhibitors include inhibitors of PI3Ky, PI3K5, PI3KB, , and/or pan-PI3K.

Examples of PI3K inhibitors include, but are not limited to, wortmannin, BKM120, CH5132799, XL756, and GDC-0980.

Examples of PI3Ky inhibitors include, but are not limited to, 4, 24, LY294002, and TG100115.

Examples of PI3K5 inhibitors include, but are not limited to, PI3K II, TGR-1202, AMG- 319, GSK2269557, X-339, X-414, RP5090, KAR4141, XL499, OXY111A, IPI-145, IPI-443, and the compounds described in WO 13556 (ICOS), (Gilead Calistoga), WO 16562 (Gilead Calistoga), W0 2014/100765 (Gilead Calistoga), W0 2014/100767 (Gilead Calistoga), and (Gilead Sciences).

Examples of PI3KB inhibitors include, but are not limited to, 6771, BAY 10824391, and TGX221.

Examples of PI3KOL tors include, but are not limited to, buparlisib, BAY 80-6946, BYL719, PX-866, , MLN1117, WX-037, AEZA-129, and PA799.

Examples ofpan-PI3K inhibitors e, but are not d to, LY294002, BEZ235, XL147 (SAR245408), and GDC-0941.

Examples of SYK inhibitors include, but are not limited to, tamatinib (R406), fostamatinib (R788), PRT062607, BAY3606, NVP-QAB 205 AA, R112, R343, and those described in US Patent No.: 8,450,321 (Gilead Connecticut).

TKIs may target epidermal growth factor receptors (EGFRs) and receptors for fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor . Examples of TKIs that target EGFR include, but are not limited to, gefitinib and erlotinib. Sunitinib is a non-limiting e of a TKI that targets receptors for FGF, PDGF, and VEGF.

The anti-PD-Ll antibodies ofthe present disclosure can be used, in some embodiments, together with an immune checkpoint inhibitor. Immune checkpoints are molecules in the immune system that either turn up a signal (co-stimulatory les) or turn down a signal (co- inhibitory molecules). Many cancers protect themselves from the immune system by inhibiting D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by r [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] r MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar the T cell signal through agonist for co-inhibitory molecules or antagonist for co-stimulatory molecules. An immune checkpoint agonist or antagonist can help stop such a protective ism by the cell cells. An immune checkpoint t or antagonistmay target any one or more ofthe following checkpoint molecules, PD-l, CTLA-4, LAG-3 (also known as CD223), CD28, CD122, 4-1BB (also known as CD137), TIM3, OX-40/OX40L, CD40/CD40L, LIGHT, ICOS/ICOSL, GITR/GITRL, TIGIT, CD27, VISTA, B7H3, B7H4, HEVM or BTLA (also known as CD272).

Programmed T cell death 1 (PD-1) is a trans-membrane protein found on the surface of T cells, which, when bound to programmed T cell death ligand 1 (PD-L1) on tumor cells, results in suppression of T cell activity and reduction of T cell-mediated cytotoxicity. Thus, PD-l and PD- L1 are immune down-regulators or immune checkpoint “off switches”. Example PD-l inhibitor include, without limitation, nivolumab, (Opdivo) (EMS-93 6558), pembrolizumab (Keytruda), pidilizumab, AMP-224, MEDIO680 14), PDROOl, MPDL3280A, MEDI4736, BMS- 936559 and MSB0010718C.

CTLA-4 is a n receptor that downregulates the immune system. Non-limiting examples of CTLA-4 inhibitors include ipilimumab ) (also known as EMS-734016, MDX-OlO, MDX-lOl) and tremelimumab (formerly ticilimumab, CP-675,206).

Lymphocyte-activation gene 3 (LAG-3) is an immune checkpoint receptor on the cell e works to suppress an immune response by action to Tregs as well as direct effects on CD8+ T cells. LAG-3 inhibitors include, without limitation, LAG525 and EMS-986016.

CD28 is constitutively expressed on almost all human CD4+ T cells and on around half of all CD8 T cells. prompts T cell expansion. Non-limiting examples of CD28 inhibitors include TGN1412.

CD122 increases the eration of CD8+ effector T cells. Non-limiting examples include NKTR—214. 4-1BB (also known as CD137) is ed in T-cell proliferation. CD137-mediated signaling is also known to protect T cells, and in particular, CD8+ T cells from activation- induced cell death. PF-05082566, ab (EMS-663513) and lipocalin are example CD137 inhibitors.

D ation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] r Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar For any of the above combination treatments, the anti-PD-Ll antibody can be administered concurrently or separately from the other anticancer agent. When administered separately, the anti-PD-Ll dy can be administered before or after the other anticancer agent.

Treatment ofInfections As demonstrated in the mental examples, the antibodies of the present disclosure can activate immune se which can then be USCfill for treating infections.

Infection is the invasion of an organism’s body tissues by e-causing agents, their multiplication, and the reaction of host tissues to these organisms and the toxins they produce.

An infection can be caused by infectious agents such as viruses, viroids, prions, bacteria, nematodes such as parasitic roundworms and pinworms, arthropods such as ticks, mites, fleas, and lice, fiJngi such as ringworm, and other arasites such as tapeworms and other helminths. In one aspect, the infectious agent is a bacterium, such as Gram negative bacterium.

In one , the infectious agent is virus, such as DNA viruses, RNA viruses, and reverse transcribing viruses. Non-limiting es of viruses include Adenovirus, kievirus, Epstein—Barr virus, Hepatitis A virus, Hepatitis B virus, Hepatitis C virus, Herpes x virus, type 1, Herpes simplex virus, type 2, Cytomegalovirus, Human herpesvirus, type 8, HIV, Influenza virus, Measles virus, Mumps virus, Human papillomavirus, Parainfluenza virus, Poliovirus, Rabies virus, Respiratory syncytial virus, Rubella virus, Varicella—zoster virus.

The antibodies ofthe present disclosure can also be used to treat an infectious disease caused by a microorganism, or kill a microorganism, by targeting the microorganism and an immune cell to effect elimination of the rganism. In one aspect, the microorganism is a virus including RNA and DNA viruses, a Gram positive bacterium, a Gram negative bacterium, a protozoa or a fungus. Non-limiting examples of infectious diseases and related microorganisms are provided in Table 4 below.

Table 4. ious diseases and related rganism sources.

Infectious Disease Micr00r_anism Source Acinetobacter infections Acinetobacter baumannii Actinomycosis Actinomyces israelii, Actinomyces gerencseriae and Pro: ionibacterium I ran ionicus African slee in- sickness (African [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar t uanosomiasis) AIDS (Acquired immunodeficiency HIV (Human deficiency virus) s ndrome Amebiasis Entamocba histol tica Anaulasmosis Anthrax Bacillus anthracis Arcanobacterium yticum bactcrium hacmolyticum infection Argentine hemorrhagic fever Junin virus Ascariasis Ascaris lumbricoides Aspergillosis Astrovirus ion Astroviridac famil Babesiosis Bacillus cereus infection Bacterial pneumonia Bacterial va'nosis (BV) multi .le bacteria Bacteroides infection Balantidiasis Baylisascaris infection Baylisascaris genus BK virus infection BK virus Black piedra Piedraia hortac Blastoc stis s infection c stis s Blastomycosis myces dermatitidis Bolivian hemorrha'c fever Machuto virus Borrelia ion Botulism (and Infant botulism) idium botulinum Brazilian hemorrhaic fever Brucellosis Burkholderia infection usually Burkholderia cepacia and other Burkholderia s uecies Buruli ulcer M cobactcrium ulcerans Calicivirus infection (Norovirus and Caliciviridac family Saovirus Cam. lobacteriosis Candidiasis (Moniliasis; Thrush) Cat-scratch disease Cellulitis Chagas Disease (American Trypanosoma cruzi trvpanosomiasis) Chancroid Hacmmhilus ducrc i Chickenpox Varicella zoster virus (VZV) Chlam dia Chlam dia trachomatis Chlam do uhila uneumoniae infection Cholera Chromoblastom cosis Clonorchiasis Clostridium difficile infection Coccidioidom cosis Colorado tick fever CTF Common cold (Acute viral [Annotation] r None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar rhino uha nitis; Acute co za) Creutzfeldt-Jakob disease (CJD) CJD prion Crimean-Congo hemorrhagic fever n-Congo hemorrhagicfever virus (CCHF) C cosis C cus ne0 0rmans C outosoridiosis C ”tosoridium enus Cutaneous larva mirans (CLM) usuall Anc lostoma iense; multitle other tarasites C closoriasis C Clostora ca etanensis C sticercosis Taenia solium C tomealovims ion C tomealovirus Dengue fever Dengue viruses (DEN-I, DEN-2, DEN-3 and DEN-4) — Flaviviruses Dientamoebiasis Dientamoeba railis Di 0 a C0 nebacterium diththeriae Diphyllobothriasis Diphyllobothrium Dracunculiasis Dracunculus medinensis Ebola hemorrhaic fever Ebolavirus (EBOV) Echinococcosis Echinococcus enus Ehrlichiosis Ehrlichia genus Enterobiasis (Pinworm infection) Enterobius vermicularis Enterococcus infection Enterococcus genus Enterovims infection Enterovirus enus Epidemic typhus Rickettsia prowazekii E thema infectiosum (Fifth disease) irus B19 Exanthem subitum (Sixth disease) Human herpesvirus 6 (HHV-6) and Human herpesvirus 7 HHV-7 Fasciolo o siasis FasCiOstis buski Fasciolosis Fasciola hetatica and Fasciola iantica Fatal familial insomnia (FFI) FFI tri0n Filariasis Filarioidea suterfamil Food poisoning by Clostridium Clostridium perfringens u,erfrinens Free-livin amebic infection multi 0 le cterium infection Fusobacterium enus Gas gangrene (Clostridial y Clostridium perfringens; other Clostridium m onecrosis) s uecies Geotrichosis chum candidum Gerstmarm—Straussler-Scheinker GSS prion s ndrome (GSS) Giardiasis Glanders Gnathostomiasis Gonorrhea Granuloma in inale Donovanosis Grou. A stre tococcal infection Grou. B stre tococcal infection Haemo uhilus influenzae infection Hand, foot and mouth disease viruses, mainly Coxsackie A virus and Enterovirus HFMD 71 V71 Hantavims Pulmona S ndrome Sin Nombre virus [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r (HPS) Hemol tic-uremic s ndrome (HUS) Escherichia coli 0]57:H7, 01]] and 0]04:H4 s ndrome HFRS Heatitis A He atitis B Heatitis C He atitis D He atitis E tis E Virus He es simleX Hertes simtlex virus 1 and 2 (HSV-l and HSV-2) Histoplasmosis Histoplasma capsulatum Hookworm ion Anc lostoma duodenale and Necator americanus Human bocaVims infection Human bocavirus (HBoV) Human ewinii ehrlichiosis Ehrlichia ewin ii Human granulocytic anaplasmosis Anaplasma phagocytophilum (HGA) Human metaoneumovirus infection Human metatneumovirus (hMPV) Human monocytic ehrlichiosis Ehrlichia chafieensis Human papillomaVirus (HPV) Human papillomavirus (HPV) infection Human arainfluenza Virus infection Human :arain uenza viruses HPI H menole iasis H menOleliS nana and H menOleliS diminuta Mononucleosis Mono Influenza (flu) Isosoriasis ki disease unknown; evidence su: torts that it is in ectious Keratitis Kuru Kuru trion Lassa fever Le-ionellosis nnaires' disease) Le osis (Pontiac fever) Leionella lineumOhila Leishmaniasis Leishmania enus Le ros M cobacterium letrae and M erium letromatosis Le tos irosis Letttosira enus ListeIiosis Listeria monoc t0enes L me disease (L me borreliosis) usuall Borrelia burdor eri and other Borrelia suecies L mhatic filariasis (Elehantiasis) Wuchereria bancro ti and Bruia mala i L mhoc tic choriomeninitis L mlhOC tic chariomeninitis virus (LCMV) Malaria Plasmodium genus Marbur hemorrhaic fever (MHF) Marbur virus s Measles virus Melioidosis (Whitmore's disease) Burkholderia seudomallei Meninitis multi I le Meninococcal disease Neisseria meninitidis Metaonimiasis usuall Metaonimus okaawai Micros OIidiosis Microstoridia 1h lum Molluscum contaiosum (MC) Molluscum conta i0sum virus (MCV) [Annotation] r None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] r Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar Mums Mumts virus MW”mm“) M co lasma neumonia M colasma neumoniae urii (Eum cetoma) M iasis orum) ; anorrhoeae disease vCJD,nvCJD Nocardiosis usuall Nocardia asteroides and other Nocardia suecies Onchocerciasis (River blindness) Onchocerca v0lvulus Paracoccidioidomycosis (South Paracoccidioides brasilierisis American m cosis) Paragonimiasis y Paragonimus mani and other nimus s uec1es Pasteurellosis Pasteurella enus Pediculosis caitis (Head lice) Pediculus humanus caitis Pediculosis CO 00115 Bod lice Pediculus humanus C0r10ris Pediculosis pubis (Pubic lice, Crab us pubis lice) Pelvic inflamniato disease (PID) Pertussis (Whoo in- cou-h) Pia- e Pneumococcal infection Pneumoc stis nia (PCP) Pneumonia n elitis PreVotella infection Primary amoebic usually Naegleria fowleri meninoence halitis PAM Progressive multifocal JC virus leukoencephalopathy Psittacosis Chlam dathila :sittaci Rabies Rat-bite fever Res irato s nc tial virus infection Rhinovirus infection Rhinovirus Rickettsial ox Rickettsia akari Rift Valley fever (RVF) Rift Valleyfever virus Rocky mountain spotted fever Rickettsia rickettsii (RMSF) Rotavirus infection Rubella Rubella virus Salmonellosis Salmonella enus SARS (Severe Acute Respiratory SARS C0r0navirus S ndrome) [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar Scabies Sarco I tes scabiei SeoSiS multitle Shi-ellosis Bacilla d sente Shinles (He es zoster) Small -0X (Vafiola) S 0r0tll'chosis Stah al food oisonin- Stah 10000031 infection Stron- sis S thilis Taeniasis Tetanus (Lock'aW) Tinea barbae (Barber's itch) usually Trichophyton genus Tinea ca itis (Rin orm of the Seal) usuall Trichoh ton tonsurans Tinea corporis (Ringworm of the usually Trichophyton genus Tinea cruIis (Jock itch) usually Epidermophytonfloccosum, Trichophyton rubrum, and Trichophyton rophytes Tinea manuum (Ringworm of the Trichophyton rubrum Hand) usuall Hortaea kii Tinea uedis (Athlete’s foot) usuall h ton enus Tinea un ium (On chom cosis) usuall Trichoth ton enus versicolor) Toxocaiiasis (Visceral Larva Migrans Toxo lasmosis Tnchinellosis Tnchomoniasis Tnchuiiasis (Whiworm ion) Tuberculosis Ureaelasma ureal ticum ion Urealasma urea] ticum Venezuelan ecuine ence halitis Venezuelan hemorrha-ic fever Viral neumonia West Nile Fever White iedra (Tinea blanca) Yersinia useudotuberculosis infection Yersiniosis Yersim'a enterocolitica Yellow fever Yellow ever virus Zygomycosis Mucorales order (Mucormycosis) and Entomophthorales order (Entomoththoram cosis) [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] wilksar Unmarked set by wilksar A c dosage and treatment regimen for any particular patient will depend upon a variety of s, including the particular antibodies, variant or derivative thereof used, the patient's age, body weight, general , sex, and diet, and the time of administration, rate of excretion, drug combination, and the severity ofthe particular disease being treated. Judgment of such factors by medical caregivers is within the ry skill in the art. The amount will also depend on the individual patient to be treated, the route of administration, the type of ation, the characteristics of the compound used, the severity of the e, and the desired effect. The amount used can be determined by pharmacological and pharmacokinetic principles well known in the art.

Methods of stration of the antibodies, variants or include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The antigen-binding polypeptides or compositions may be administered by any convenient route, for e by SlOl’l or bolus injection, by absorption through lial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Thus, pharmaceutical compositions containing the antigen-binding polypeptides of the disclosure may be administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, drops or transdermal patch), bucally, or as an oral or nasal spray.

The term “parenteral” as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrastemal, subcutaneous and intra-articular injection and infusion.

Administration can be systemic or local. In addition, it may be ble to introduce the antibodies of the disclosure into the central nervous system by any le route, including entricular and hecal injection, intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir.

Pulmonary administration can also be employed, e.g., by use of an r or nebulizer, and formulation with an aerosolizing agent.

It may be desirable to ster the antibodies polypeptides or compositions of the disclosure locally to the area in need of treatment, this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction, with D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar a wound dressing after surgery, by ion, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material, including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the disclosure, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the antibodies or composition can be delivered in a vesicle, in particular a me (see Langer, 1990, e 249: 1527-1533, Treat et al, in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 353-365 (1989), Lopez-Berestein, ibid., pp. 317-327, see generally ibid.) In yet another embodiment, the antigen-binding polypeptide or composition can be delivered in a lled release system. In one embodiment, a pump may be used (see Sefton, 1987, CRC Crit. Ref. Biomed. Eng. , Buchwald et al., 1980, Surgery 88:507, Saudek et al, 1989, N. Engl. J. Med. 321:574). In another embodiment, ric materials can be used (see Medical Applications of Controlled Release, Langer and Wise (eds.), CRC Pres., Boca Raton, Fla. (1974), lled Drug Bioavailability, Drug Product Design and Performance, Smolen and Ball (eds.), Wiley, New York (1984), Ranger and Peppas, J., 1983, Macromol. Sci.

Rev. Macromol. Chem. 23:61, see also Levy et al, 1985, Science 228: 190, During et al, 1989, Ann. Neurol. 25:351, Howard et al, 1989, J. Neurosurg. 71:105). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i. e., the brain, thus requiring only a on ofthe systemic dose (see, e. g., Goodson, in Medical Applications of Controlled Release, supra, vol. 2, pp. 115-138 (1984)). Other lled release systems are sed in the review by Langer (1990, e 249:1527-1533).

In a specific embodiment where the composition ofthe disclosure comprises a nucleic acid or polynucleotide encoding a protein, the nucleic acid can be administered in vivo to e eXpression of its encoded protein, by constructing it as part of an riate nucleic acid eXpression vector and administering it so that it becomes intracellular, e. g., by use of a retroviral vector (see US. Pat. No. 4,980,286), or by direct injection, or by use of article dment (e. g., a gene gun, Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox-like peptide which is known to enter the nucleus (see, e. g., Joliot et al, 1991, Proc. Natl. Acad. Sci. USA D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar 88: 1864-1868), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The amount of the antibodies of the disclosure which will be effective in the treatment, tion and prevention of an inflammatory, immune or malignant disease, disorder or condition can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify l dosage . The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness ofthe disease, disorder or condition, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose- response curves derived from in vitro or animal model test systems.

As a general proposition, the dosage administered to a patient ofthe antigen-binding polypeptides of the present disclosure is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight, between 0.1 mg/kg and 20 mg/kg ofthe patient's body weight, or 1 mg/kg to 10 mg/kg ofthe patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower s of human antibodies and less frequent administration is often possible. Further, the dosage and ncy of administration of antibodies of the sure may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The methods for treating an infectious or malignant disease, condition or disorder comprising administration of an antibody, variant, or derivative thereof of the disclosure are typically tested in vitro, and then in vivo in an acceptable animal model, for the desired eutic or lactic ty, prior to use in humans. le animal models, including transgenic s, are well known to those of ordinary skill in the art. For e, in vitro assays to demonstrate the therapeutic utility of antigen-binding polypeptide bed herein include the effect of an antigen-binding polypeptide on a cell line or a patient tissue sample. The effect ofthe n-binding polypeptide on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art, such as the assays disclosed elsewhere herein. In accordance with the disclosure, in vitro assays which can be used to determine whether administration of a specific antigen-binding polypeptide is indicated, include in vitro D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] wilksar Unmarked set by wilksar cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a nd, and the effect of such compound upon the tissue sample is observed.

Various delivery s are known and can be used to administer an dy ofthe disclosure or a polynucleotide encoding an antibody of the disclosure, 6. g., encapsulation in liposomes, microparticles, microcapsules, inant cells capable of expressing the nd, receptor-mediated endocytosis (see, e.g., Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432), construction of a nucleic acid as part of a iral or other vector, etc.

Diagnostic Methods Over-expression of PD-Ll is observed in certain tumor samples, and patients having PD- Ll-over-eXpressing cells are likely responsive to treatments with the anti-PD-Ll antibodies of the present disclosure. Accordingly, the antibodies of the present disclosure can also be used for diagnostic and prognostic purposes.

A sample that preferably includes a cell can be ed from a patient, which can be a cancer patient or a patient desiring diagnosis. The cell be a cell of a tumor tissue or a tumor block, a blood sample, a urine sample or any sample from the t. Upon optional pre- treatment ofthe sample, the sample can be incubated with an antibody of the present disclosure under conditions allowing the antibody to ct with a PD-Ll protein ially present in the sample. Methods such as ELISA can be used, taking advantage of the anti-PD-Ll antibody, to detect the presence of the PD-Ll protein in the sample.

Presence ofthe PD-Ll protein in the sample (optionally with the amount or concentration) can be used for diagnosis of cancer, as an indication that the patient is suitable for a treatment with the antibody, or as an indication that the patient has (or has not) responded to a cancer treatment. For a prognostic method, the detection can be done at once, twice or more, at certain stages, upon initiation of a cancer treatment to indicate the progress of the treatment.

Compositions The present sure also es pharmaceutical itions. Such compositions comprise an effective amount of an antibody, and an acceptable carrier. In some embodiments, D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by r ation] wilksar ionNone set by r [Annotation] wilksar Unmarked set by wilksar the composition fithher includes a second ncer agent (e.g., an immune checkpoint inhibitor).

In a specific embodiment, the term “pharmaceutically acceptable” means approved by a regulatory agency of the Federal or a state government or listed in the US. Pharmacopeia or other generally recognized copeia for use in animals, and more particularly in humans.

Further, a “pharmaceutically acceptable carrier” will generally be a non-toxic solid, semisolid or liquid filler, t, encapsulating material or formulation auxiliary of any type.

The term “carrier” refers to a diluent, adjuvant, excipient, or e with which the therapeutic is administered. Such ceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable ceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, ol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of g or emulsifying agents, or pH buffering agents such as acetates, citrates or phosphates. Antibacterial agents such as benzyl alcohol or methyl parabens, antioxidants such as ascorbic acid or sodium bisulfite, chelating agents such as ethylenediaminetetraacetic acid, and agents for the adjustment oftonicity such as sodium chloride or dextrose are also envisioned. These compositions can take the form of solutions, sions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with ional binders and carriers such as triglycerides. Oral formulation can e standard rs such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable pharmaceutical carriers are bed in Remington's Pharmaceutical Sciences by E. W. Martin, incorporated herein by reference.

Such compositions will contain a therapeutically effective amount of the antigen-binding polypeptide, preferably in purified form, together with a suitable amount of r so as to provide the form for proper administration to the patient. The formulation should suit the mode D [Annotation] r None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar of administration. The parental preparation can be enclosed in ampoules, disposable syringes or le dose vials made of glass or plastic.

In an embodiment, the ition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human . lly, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site ofthe inj ection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for e, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds ofthe disclosure can be formulated as neutral or salt forms.

Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, ium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, ne, etc.

EXAMPLES e 1: Generation of human monoclonal dies against human PD-L1 Anti-human-PD-Ll mouse onal antibodies were generated using the hybridoma technology.

Antigen: human PDLl-Fc protein and human PD-Ll highly expressed CHOKl cell line (PDLl- CHOKl cell line). zation: To generate mouse monoclonal antibodies to human PD-Ll, 6-8 week female BALB/c mice were firstly immunized with 1.5 X 107 PDLl- CHOKl cells. Day 14 and 33 post first immunization, the zed mice were re-immunized with 1.5 X 107 PDLl- D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar ionNone set by r [Annotation] wilksar ed set by wilksar CHOKl cells respectively. To select mice producing antibodies that bond PD-Ll protein, sera from immunized mice were tested by ELISA. Briefly, microtiter plates were coated with human PD-Ll protein at l ug/ml in PBS, 100ul/well at room temperature (RT) overnight, then blocked with lOOul/well of 5% BSA. Dilutions ma from immunized mice were added to each well and incubated for 1-2 hours at RT. The plates were washed with PBS/Tween and then incubate with anti-mouse IgG antibody conjugated with Horse Radish Peroxidase (HRP) for 1 hour at RT. After washing, the plates were ped with ABTS substrate and analyzed by spectrophotometer at OD 405nm. Mice with sufficient titers of DLl IgG were boosted with 50ug human PDLl-Fc protein at Day 54 post-immunization. The resulting mice were used for fusions. The hybridoma supematants were tested for anti-PD-Ll IgGs by ELISA. oma clones HL1210-3, HL1207-3, HL1207-9 and HL1120-3 were selected for fithher analysis. The amino acid and polynucleotide sequences of the variable regions of HL1210-3 are provided in Table 5 below.

Table 5. HL1210-3 variable sequences Name Se a uence SEQ ID NO: HL12H)3\GI GAAGTGAAACTGGTGGAGTCTGGGGGAGACTTAGTGAAGC 112 CTGGAGGGTCCCTGAAACTCTCCTGTGCAGCCTCTGGATT CACIIICAGIAGCIAIGACAIGICIIGGGIICGCCAGACT CCGGAGAAGAGTCTGGAGTGGGTCGCAACCATTAGTGATG GTGGTGGTTACATCTACTATTCAGACAGTGTGAAGGGGCG ATTTACCATCTCCAGAGACAATGCCAAGAACAACCTGTAC CTGCAAATGAGCAGTCTGAGGTCTGAGGACACGGCCTTGT ATATTTGTGCAAGAGAATTTGGTAAGCGCTATGCTTTGGA CTACTGGGGTCAAGGAACCTCAGTCACCGTCTCCTCA HL12HL3\G{ *SGGDLVKPGGSL(ESCAASGFTFSSYDMSWVRQT 113 *WVAIISDGGGYIYYSDSVKGRFTISRDNAKNNLY .RSTDTALYICARTFGKRYALDYWGQGTSVT HL12H)3\HJ GACATTGTGATGACCCAGTCTCACAAATTCATGTCCACAT 114 GAGACAGGGTCAGCATCTCCTGCAAGGCCAGTCA GGAIGIGACICCIGCIGICGCCIGGIAICAACAGAAGCCA GGACAAICICCIAAACIACIGAIIIACICCACAICCICCC GGIACACIGGAGICCCIGAICGCIICACIGGCAGIGGAIC TGGGACGGATTTCACTTTCACCATCAGCAGTGTGCAGGCT CTGGCAGTTTATTACTGTCAGCAACATTATACTA CTCCGCTCACGTTCGGTGCTGGGACCAAGCTGGAGCTGAA -GQSPKLLIYSISSRYIGVPDRE IGSGSGIDI:HL12HL3\HJ DIVMTQSHKFMSTSVGDRVSISCKASQDVTPAVAWYQQKP 115 ll: IISSVQA EDLAVYYCQQHYTTPLTFGAGTKLELK [Annotation] wilksar None set by wilksar ation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar Example 2: HL1210-3 mouse monoclonal antibody’s binding activity for human PD-Ll To evaluate the g ty of hybridoma clone HL1210-3, the purified mAb from this clone were subjected to ELISA test. Briefly, microtiter plates were coated with human PD- Ll-Fc protein at 0.1 [Lg/ml in PBS, lOOul/well at 4°C overnight, then blocked with lOOul/well of % BSA. Three-fold dilutions of HL1210-3 antibodies starting from 0.2 ug/ml were added to each well and ted for 1-2 hours at RT. The plates were washed with PBS/Tween and then incubate with goat-anti-mouse IgG antibody conjugated with Horse Radish dase (HRP) for 1 hour at RT. After washing, the plates were ped with TMB substrate and analyzed by spectrophotometer at OD 450-630nm. As shown in HL1210-3 can bind to human PD-Ll with high activity 5.539ng/ml).

Example 3: HL1210-3 mouse mAb d human PD-Ll binding to its receptor PD-l Receptor blocking assay by using recombinant human PD-L] To evaluate the blocking effect of HL1210-3 mouse mAb on recombinant human PD-Ll to bind to its receptor PD-l, the ELISA based receptor blocking assay was ed. Briefly, microtiter plates were coated with human PD-Ll-Fc protein at lug/m1 in PBS, well at 4°C overnight, then blocked with lOOul/well of 5% BSA. 50ul biotin-labeled human PD-l-Fc protein and 3-fold dilutions of HL1210-3 antibodies starting from Zug/ml at 50ul were added to each well and incubated for 1 hour at 37°C. The plates were washed with PBS/Tween and then incubated with Streptavidin-HRP for 1 hour at 37°C. After washing, the plates were developed with TMB substrate and analyzed by spectrophotometer at OD 45 0-63Onm. As shown in HL1210-3 can efficiently inhibit the binding of human PD-Ll to human PDl at IC50=0.7835nM.

Receptor blocking assay by using ian cell expressed human PD-L] To evaluate the blocking effect of HL1210-3 mouse mAb on human PD-Ll expressed on mammalian cells to bind to its receptor PD-l, the ased receptor blocking assay was used. Briefly, PDLl-CHOKl cells were firstly incubated with 3-fold serious diluted HL1210-3 mouse mAb starting at 20ug/ml at RT for 1 hour. After wash by FACS buffer (PBS with 2% FBS), the biotin-labeled huPD-l were added to each well and incubated at RT for 1 hour. Then, the Streptavidin-PE were added to each well for 0.5 hour post twice wash with FACS buffer.

B [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] wilksar Unmarked set by wilksar The mean florescence intensity (MFI)of PE were evaluated by FACSAriaIII. As shown in the HL1210-3 antibody can highly efficiently inhibit the binding of PD-l on PD-Ll expressed on mammalian cells at IC50 of 2.56nM with 92.6% top inhibition rate.

MFI oftesting antibody % ofinhibition= (1 — MFI ofvehicle contorl )x 100% Example 4: HL1210-3 mouse mAb promoted human T cell immune response To evaluate the effect of -3 mouse mAb, the response ofhuman T cells assessed in a mixed lymphocyte reaction setting. Human DCs were differentiated from CDl4+ monocytes in the presence of GM-CSF and IL-4 for 7 days. CD4+ T cells isolated from another donor were then co-cultured with the DCs and serial dilutions of D-Ll blocking antibody.

At day 5 post-inoculation, the culture supernatant was assayed for IFNy tion. The s indicated that the HL1210-3 antibodies can dose-dependently promote IFNy production, suggesting anti-PD-Ll antibody can promote human T cell response (. e 5: The binding ty of -3 mouse mAb The g ofthe HL1210-3 antibodies to recombinant PD-Ll protein (human PD-Ll- his taq) was tested with BIACORETM using a capture method. The -3 mouse mAb was captured using anti-mouse Fc antibody coated on a CMS chip. A series dilution ofhuman PD- Ll-his taq protein was injected over captured antibody for 3 mins at a flow rate of 25 ug/ml. The n was allowed to dissociate for 900s. All the experiment were carried out on a Biacore T200. Data analysis was carried out using Biacore T200 evaluation software. The result are shown in and Table 6 below.

Table 6. Binding Kinetics ofHL1210-3 to recombinant human PD-L] Antibod ka (l/Ms) kd (1/s) HL1210-3 1.61E+05 4.69E-05 2.93E-10 Example 6: Humanization 0f the HL1210-3 mouse mAb The mAb HL1210-3 variable region genes were employed to create a humanized MAb.

In the first step of this process, the amino acid sequences ofthe VH and VK of MAb HL1210-3 were compared against the ble database ofhuman Ig gene sequences to find the overall D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar best-matching human germline Ig gene sequences. For the light chain, the closest human match was the OlS/Jk2 and KVl-39*Ol/KJ2*04 gene, and for the heavy chain the closest human match was the VH3-21 gene. VH3-l l, VH3-23, Ol and VH3-48 genes were also ed due to their close matches. zed variable domain sequences were then designed where the CDRl (SEQ ID N04), 2 (SEQ ID N05) and 3 (SEQ ID NO.6) of the HL1210-3 light chain were grafted onto framework sequences of the OlS/Jk2 and KVl-39*Ol/KJ2*04 gene, and the CDRl (SEQ ID No.1), 2 (SEQ ID N02), and 3 (SEQ ID NO.3) sequences ofthe HL1210-3 VH were grafted onto framework sequences of the VH3-21, VH3-l l, VH3-23, VH3-48 or VH3-7*Ol gene. A 3D model was then ted to determine if there were any framework positions where replacing the mouse amino acid to the human amino acid could affect binding and/or CDR mation.

In the case ofthe light chain, 22S, 43S, 60D, 63T and 42Q (Kabat ing, see Table 7) in framework were identified. In the case of the heavy chain, lE, 37V, 40T, 44S, 49A, 77N, 9lI, 94R and 108T in the framework was involved in back-mutations.

Table 7. Humanization Design VH Design I: VH3-21/JH6 Construct Mutation Hu1210 VH Chimera Hu1210 VH.1 afted Hu1210 VH.la S49A Hu1210 VH.1b S49A, G44S, Y911 VH Design 11: VH3-11/JH6 Hu1210 VH.2 CDR-grafted, QlE Hu1210 VHZa QlE, S49A Hu1210 VH.2b Q1E,I37V, S49A, G44S, Y911 VH Design 111: VH3-23/JH6 Hu1210 VH.3 CDR-grafted, K94R Hu1210 VH.3a G44S, S49A, Y9lI, K94R VH Design IV: VH3-48/JH6 Hu1210 VH.4 CDR-grafted Hu1210 VH.4a S49A [Annotation] wilksar None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] r MigrationNone set by wilksar [Annotation] r Unmarked set by wilksar Hu1210 VH.4b S49A, G44S, Y911 Hu1210 VH.4C D52E, S49A, G44S, Y911 Hu1210 VH.4d G53A, S49A, G44S, Y911 Hu1210 VH.4e G53V, S49A, G44S, Y911 VH Design V : VH3—7*01/HJ1*01 Hu1210 VH.5 CDR-grafted Hu1210 VH.53 H9 11 Hu1210 VH.5b H911, H108T Hu1210 VH.5C H911, H77N Hu1210 VH.5d H911, H77N, H40T VK Design 1: 018/Jk2 Construct Mutation Hu1210 Vk Chimera Hu1210 Vk.1 CDR-grafted Hu1210 Vk.la A43 S VK Design 11: KV1-39*01/KJ2*04 Hu1210 Vk.2 CDR-grafted Hu1210 Vk.Za L60D, L63T Hu1210 Vk.2b L60D, L63 T, L42Q, L43 S Hu1210 Vk.2c L60D, L63T, L42Q, L43 S, T228 The amino acid and nucleotide sequences of some of the zed antibody are listed in Table 8 below.

Table 8. Hamanized antibody sequences (bold indicates CDR) Name Sequence HLl 2 1 0 ,VH EVKJVE SGGDJVKP GGSHKHSCAASGFT ? WVRQTPEKSJEWVAT ISDGGGYIYYSDSVKGRrTI sRDNAKNNJY,JQMSS,JRSEDTALYICAREF GKRYALDYWGQGTSVTVSS HulZlO VH.l EVQJVESGGGJVKPGGSJRJSCAASGFTrSSYDMSWVRQAPGKGJEWVST ISDGGGYIYYSDSVKGRrTISRDNAKNSJYJQMNSJRAEDTAVYYCAREF GKRYALDYWGQGTTVTVSS HulZlO VH.la, EVQJVESGGGJVKPGGSJRJSCAASGFTrSSYDMSWVRQAPGKGJEWVAT ISDGGGYIYYSDSVKGRrTISRDNAKNSJYJQMNSJRAEDTAVYYCAREF GKRYALDYWGQGTTVTVSS Hul210 VH_lk) EVQJVESGGGJVKPGGSJRJSCAASGFTrSSYDMSWVRQAPGKSJEWVAT ISDGGGYIYYSDSVKGR:TISRDNAKNSJYJQMNSJRAEDTAVYICAREF GKRYALDYWGQGTTVTVSS [Annotation] wilksar None set by r [Annotation] wilksar ionNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar ul2lO V EVQJVESGGGJVKDGGSJ?JSCAASG r"?SSYDMSWI 11 ISDGGGYIYYSDSVKG a?“IS 84$ GKRYALDYWGQthvhvss EVQJVESGGGV jGGS ISDGGGYIYYSDSVKG q.

GKRYALDYWGQG""V"VSS EVQJVESGGGJVKDGGSr? ISDGGGYIYYSDSVKG a? GKRYALDYWGQG""V’ EVQJJESGGGJVQDGGS ISDGGGYIYYSDSVKG q.

GKRYALDYWGQG""V"VSS EVQJ VQDGGSr? ISDGGGYIYYSDSVKG a? GKRYALDYWGQG""V' EVQJVESGGGJVQDGGS ISDGGGYIYYSDSVKG q.

GKRYALDYWGQG""V’ SGGGJVQDGGS ISDGGGYIYYSDSVKG q.

GKRYALDYWGQG""V’ EVQJVESGGGJVQDGGS ISDGGGYIYYSDSVKG q.

GKRYALDYWGQG""V"VSS EVQJVESGGGJVQDGGSr? ISEGGGYIYYSDSVKG a? GKRYALDYWGQG""V’ EVQJVESGGGJVQDGGS ISDAGGYIYYSDSVKG q.

GKRYALDYWGQG""V"VSS EVQJVESGGGJVQDGGSr? m H ISDVGGYIYYSDSVKG a? GKRYALDYWGQG""V’ EVQJVESGGGJVQDGGS m m ISDGGGYIYYSDSVKG q.

GKRYALDYWGQGhJV’ EVQJVESGGGJVQDGGS m w ISDGGGYIYYSDSVKG q.

DYWGQGhJV’ EVQJVESGGGJVQDGGS m b ISDGGGYIYYSDSVKG q.

GKRYALDYWGQGhTV’ EVQJVESGGGJVQDGGS l\) U7 ISDGGGYIYYSDSVKG q.

GKRYALDYWGQGhJV’ EVQJVESGGGJVQDGGS l\) 0 YIYYSDSVKG 1.

GKRYALDYWGQGhJV' DIVMTQSHKF fiSVG RVSISCKASQDVTPAVAWYQQ l\) \1 TSSRYTGVPD fiGSG SG’*DFT rTISSVQA 3DLAVYYCQQHYTTPLT4 GTKJELK JSASVG DRVTITCKASQDVTPAVAWYQQ jGKAP N l\) OO RFSGSGSG’*DFT rTISSJQP3DIATYYCQQHYTTPLT4 DIQMTQSPSSJSASVG DRVTITCKASQDVTPAVAWYQQ jGKSP H l\) ‘0 TSSRYTGVPSRFSGSGSG’*DFT QP 3DIATYYCQQHYTTPLT4 GTKJEIK DIQMTQSPSS RVTITCKASQDVTPAVAWYQQ (A) O [Annotation] wilksar None set by wilksar [Annotation] r MigrationNone set by wilksar [Annotation] r Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] r MigrationNone set by wilksar ation] wilksar Unmarked set by r TSSRYTGVPSRFSGSGSGTDFTJTISSJQPEDFATYYCQQHYTTPLTFGQ GTKJEIKR DIQMTQSPSSJSASVGDRVTITCKASQDVTPAVAWYQQKPGKAPKJ TSSRYTGVPDRFTGSGSGTDFTJTISSJQPEDFATYYCQQHYTTPL GTKJEIKR DIQMTQSPSSJSASVGDRVTITCKASQDVTPAVAWYQQKPGQSPKJ (A) l\) TSSRYTGVPDRFTGSGSGTDFTJTISSJQPEDFATYYCQQHYTTPL GTKJEIKR Hul2lO Vk.2c DIQMTQSPSSJSASVGDRVTISCKASQDVTPAVAWYQQKPGQSPK” (A) (A) TSSRYTGVPDQFTGSGSGTDFTJTISSJQPEDFATYYCQQHYTTPLTFGQ GTKJEIKR HLlZlO VH AAGC"GGTGGAGAGCGGCGGAGATCTGGTGAAGCCTGGCGGCAGCCTGAAGC"G (A) b AGCTGTGCCGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGchGGGhGAGGCAGACC CCCGAGAAGAGCCTGGAGTGGGTGGCCACCATCAGCGATGGCGGCGGCTACATCTACTAC AGCGACAGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAACCTGTAC CTGCAGATGAGCAGCCTGAGGAGCGAGGACACCGCCCTGTACATchGCGCCAGGGAGT’ GGCAAGAGGTACGCCCTGGACTAC"GGGGACAGGGCACCAGCGTGACCGhGAGCAGC HulZlO VH.l GAGGTGCAGchGGTGGAGAGCGGAGGAGGACTGGTGAAGCCCGGAGGCAGCCTGAGAC’ (A) U7 AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGchGGGhGAGACAGGCC CCTGGCAAAGGCCTGGAGTGGGTGAGCACCATCTCCGATGGCGGCGGCTACATCTATTAC TCCGACAGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTAchGCGCCAGGGAGT’ GGCAAAAGGTACGCCCTGGACTAchGGGGCCAGGGCACAACCGTGACCGhGAGCAGC HulZlO VH.la, GAGGTGCAGC"GGTGGAGAGCGGAGGAGGACTGGTGAAGCCCGGAGGCAGCCTGAGACr (A) 0 AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGchGGGhGAGACAGGCC CCTGGCAAAGGCCTGGAGTGGGTGGCCACCATCTCCGATGGCGGCGGCTACATCTATTAC TCCGACAGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTAchGCGCCAGGGAGT’ GGCAAAAGGTACGCCCTGGACTAchGGGGCCAGGGCACAACCGTGACCGhGAGCAGC Hul210 VH_lb GAGGTGCAGchGGTGGAGAGCGGAGGAGGACTGGTGAAGCCCGGAGGCAGCCTGAGAC’ (A) \1 AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGchGGGhGAGACAGGCC CCTGGCAAAAGCCTGGAGTGGGTGGCCACCATCTCCGATGGCGGCGGCTACATCTATTAC TCCGACAGCGhGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACATchGCGCCAGGGAGT’ GGCAAAAGGTACGCCCTGGACTAchGGGGCCAGGGCACAACCGTGACCGhGAGCAGC HulZlO VH.2 GAGGTGCAGC"GGTGGAGAGCGGAGGAGGACTGGTGAAGCCCGGAGGCAGCCTGAGAC’ (A) OD AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGC"GGA"CAGACAGGCC CCTGGCAAAGGCCTGGAGTGGGTGAGCACCATCTCCGATGGCGGCGGCTACATCTATTAC TCCGACAGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTAchGCGCCAGGGAGT’ GGCAAAAGGTACGCCCTGGACTAchGGGGCCAGGGCACAACCGTGACCGhGAGCAGC HulZlO VH.2a, GAGGTGCAGchGGTGGAGAGCGGAGGAGGACTGGTGAAGCCCGGAGGCAGCCTGAGAC’ (A) ‘0 AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGC"GGA"CAGACAGGCC CCTGGCAAAGGCCTGGAGTGGGTGGCCACCATCTCCGATGGCGGCGGCTACATCTATTAC TCCGACAGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTAC"GCGCCAGGGAGT"C GGCAAAAGGTACGCCCTGGACTAC"GGGGCCAGGGCACAACCGTGACCGhGAGCAGC HulZlO VH.2b GAGGTGCAGC"GGTGGAGAGCGGAGGAGGACTGGTGAAGCCCGGAGGCAGCCTGAGAC"G AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGchGGGhGAGACAGGCC AAAAGCCTGGAGTGGGTGGCCACCATCTCCGATGGCGGCGGCTACATCTATTAC TCCGACAGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACATchGCGCCAGGGAGT’ GGCAAAAGGTACGCCCTGGACTAC"GGGGCCAGGGCACAACCGTGACCGhGAGCAGC Hul2lO VH.3 GAGGTGCAGchGCTGGAGAGCGGAGGAGGACTGGTGCAACCCGGAGGCAGCCTGAGAC’ b i—‘ AGCTGCGCTGCCAGCGGCTTCAcchTCAGCAGCTACGACATGAGchGGGhGAGACAGGCC CCTGGCAAAGGCCTGGAGTGGGTGAGCACCATCTCCGATGGCGGCGGCTACATCTATTAC TCCGACAGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACTAC"GCGCCAGGGAGT"C GGCAAAAGGTACGCCCTGGACTAchGGGGCCAGGGCACAACCGTGACCGhGAGCAGC Hul2lO VH_3a, CAGchGCTGGAGAGCGGAGGAGGACTGGTGCAACCCGGAGGCAGCCTGAGAC"G J> l\) AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGchGGGhGAGACAGGCC [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] r ed set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar CCTGGCAAAAGCCTGGAGTGGGTGGCCACCATCTCCGATGGCGGCGGCTACATCTATTAC AGCGhGAAGGGCAGGTTCACCATCAGCAGGGACAACAGCAAGAACACCCTGTAC CTGCAGATGAACAGCCTGAGGGCCGAGGACACCGCCGTGTACATC"GCGCCAGGGAGT"C AGGTACGCCCTGGACTAC"GGGGCCAGGGCACAACCGTGACCGhGAGCAGC Hul210 VH_4 GAGGTGCAGC"GGTGGAGAGCGGAGGAGGACTGGTGCAACCCGGAGGCAGCCTGAGAC’ AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGchGGGhGAGACAGGCC CCTGGCAAAGGCCTGGAGTGGGTGAGCACCATCTCCGATGGCGGCGGCTACATCTATTAC TCCGACAGCGhGAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGATGAGGACACCGCCGTGTACTAchGCGCCAGGGAGTr GGCAAAAGGTACGCCCTGGACTAC"GGGGCCAGGGCACAACCGTGACCGhGAGCAGC Hul210 VH_4a, GAGGTGCAGC"GGTGGAGAGCGGAGGAGGACTGGTGCAACCCGGAGGCAGCCTGAGAC’ AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGchGGGhGAGACAGGCC CCTGGCAAAGGCCTGGAGTGGGTGGCCACCATCTCCGATGGCGGCGGCTACATCTATTAC TCCGACAGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGATGAGGACACCGCCGTGTACTAC"GCGCCAGGGAGT"C GGCAAAAGGTACGCCCTGGACTAC"GGGGCCAGGGCACAACCGTGACCGhGAGCAGC HulZlO VH.4b GAGGTGCAGC"GGTGGAGAGCGGAGGAGGACTGGTGCAACCCGGAGGCAGCCTGAGAC"G AGCTGCGCTGCCAGCGGCTTCACChTCAGCAGCTACGACATGAGC"GGGhGAGACAGGCC CCTGGCAAAAGCCTGGAGTGGGTGGCCACCATCTCCGATGGCGGCGGCTACATCTATTAC AGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGATGAGGACACCGCCGTGTACATchGCGCCAGGGAGT"C GGCAAAAGGTACGCCCTGGACTAC"GGGGCCAGGGCACAACCGTGACCGhGAGCAGC HulZlO VH.4C GAGGTGCAGchGGTGGAGAGCGGAGGAGGACTGGTGCAACCCGGAGGCAGCCTGAGAC"G AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGchGGGhGAGACAGGCC CCTGGCAAAAGCCTGGAGTGGGTGGCCACCATCTCCGAAGGCGGCGGCTACATCTATTAC AGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGATGAGGACACCGCCGTGTACATchGCGCCAGGGAGT"C GGCAAAAGGTACGCCCTGGACTAC"GGGGCCAGGGCACAACCGTGACCGhGAGCAGC HulZlO_VH. GAGGTGCAGC"GGTGGAGAGCGGAGGAGGACTGGTGCAACCCGGAGGCAGCCTGAGAC"G AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGchGGGhGAGACAGGCC CCTGGCAAAAGCCTGGAGTGGGTGGCCACCATCTCCGATGCGGGCGGCTACATCTATTAC TCCGACAGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGATGAGGACACCGCCGTGTACATchGCGCCAGGGAGTr AGGTACGCCCTGGACTAC"GGGGCCAGGGCACAACCGTGACCGhGAGCAGC HulZlO_VH. GAGGTGCAGC"GGTGGAGAGCGGAGGAGGACTGGTGCAACCCGGAGGCAGCCTGAGACr AGCTGCGCTGCCAGCGGCTTCACC"TCAGCAGCTACGACATGAGchGGGhGAGACAGGCC CCTGGCAAAAGCCTGGAGTGGGTGGCCACCATCTCCGATGTTGGCGGCTACATCTATTAC AGCG"GAAGGGCAGGTTCACCATCAGCAGGGACAACGCCAAGAACAGCCTGTAC CTGCAGATGAACAGCCTGAGGGATGAGGACACCGCCGTGTACATchGCGCCAGGGAGTr GGCAAAAGGTACGCCCTGGACTAC"GGGGCCAGGGCACAACCGTGACCGhGAGCAGC HulZlO VH. GAGGTGCAGC"GGTGGAGTCCGGAGGAGGCCTGGTGCAACC"GGAGGCTCCCTGAGGC’ TCCTGTGCCGCT"CCGGCTTCACC"TCAGCTCCTACGATA"GAGchGGGhGAGGCAGGC’ CCTGGAAAGGGCCTGGAGTGGGTGGCCACCATCTCCGACGGAGGCGGCTACATchACTAC TCCGACTCCGhGAAGGGCAGGTTCACCATCTCCCGGGACAACGCCAAGAACTCCCTGTAC CTGCAGATGAAC"CTCTCAGGGCTGAGGACACCGCCGTGTA”TAchGCGCCAGGGAGT’ GGCAAGAGGTACGCCCTGGATTAC"GGGGCCAGGGCACAC"GGTGACAG"GAGC"CC HulZlO VH. GAGGTGCAGC"GGTGGAGTCCGGAGGAGGCCTGGTGCAACC"GGAGGCTCCCTGAGGC’ TCCTGTGCCGCT"CCGGCTTCACC"TCAGCTCCTACGATA"GAGchGGGhGAGGCAGGC’ CCTGGAAAGGGCCTGGAGTGGGTGGCCACCATCTCCGACGGAGGCGGCTACATchACTAC TCCGACTCCGhGAAGGGCAGGTTCACCATCTCCCGGGACAACGCCAAGAACTCCCTGTAC CTGCAGATGAAC"CTCTCAGGGCTGAGGACACCGCCGTGTAhATchGCGCCAGGGAGT’ GGCAAGAGGTACGCCCTGGATTAC"GGGGCCAGGGCACAC"GGTGACAG"GAGC"CC HulZlO VH. GAGGTGCAGchGGTGGAGTCCGGAGGAGGCCTGGTGCAACC"GGAGGCTCCCTGAGGC’ TCCTGTGCCGCT"CCGGCTTCACC"TCAGCTCCTACGATA"GAGchGGGhGAGGCAGGC’ CCTGGAAAGGGCCTGGAGTGGGTGGCCACCATCTCCGACGGAGGCGGCTACATchACTAC TCCGACTCCGhGAAGGGCAGGTTCACCATCTCCCGGGACAACGCCAAGAACAACCTGTAC CTGCAGATGAAC"CTCTCAGGGCTGAGGACACCGCCGTGTAhATchGCGCCAGGGAGTr GGCAAGAGGTACGCCCTGGATTAC"GGGGCCAGGGCACAC"GGTGACAGhGAGC"CC HulZlO VH. GAGGTGCAGC"GGTGGAGTCCGGAGGAGGCCTGGTGCAAcchGGAGGCTCCCTGAGGC’ TCCTGTGCCGCT"CCGGCTTCACC"TCAGCTCCTACGATA"GAGchGGGhGAGGCAGACC CCTGAGAAGAGCCTGGAGTGGGTGGCCACCATCTCCGACGGAGGCGGCTACATchACTAC [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar TCCGACTCCGTGAAGGGCAGGTTCACCATCTCCCGGGACAACGCCAAGAACAACCTGTAC CTGCAGATGAACTCTCTCAGGGCTGAGGACACCGCCGTGTATATCTGCGCCAGGGAGTTT GGCAAGAGGTACGCCCTGGATTACTGGGGCCAGGGCACACTGGTGACAGTGAGCTCC Hul2lO VH 5d GAGGTGCAGCTGGTGGAGTCCGGAGGAGGCCTGGTGCAACCTGGAGGCTCCCTGAGGCTG U7 (A) TCCTGTGCCGCTTCCGGCTTCACCTTCAGCTCCTACGATATGAGCTGGGTGAGGCAGGCT CCTGGAAAGGGCCTGGAGTGGGTGGCCACCATCTCCGACGGAGGCGGCTACATCTACTAC TCCGACTCCGTGAAGGGCAGGTTCACCATCTCCCGGGACAACGCCAAGAACTCCCTGTAC ATGAACTCTCTCAGGGCTGAGGACACCGCCGTGTATATCTGCGCCAGGGAGTTT GGCAAGAGGTACGCCCTGGATTACTGGGGCCAGGGCACAACCGTGACAGTGAGCTCC HLlZlO VK GACATCGTGATGACCCAGAGCCACAAGTTCA’TGAGCACCAGCGTGGGCGATAGGGTGAGC U7 J> TGCAAGGCCAGCCAGGATGTGACCCCTGCCGTGGCCTGGTACCAGCAGAAGCCC GGCCAGAGCCCCAAGC’*GCTGATCTACAGCACCAGCAGCAGGTACACCGGCGTGCCCGAC AGGTTCACAGGAAGCGGCAGCGGCACCGACT’*CACCTTCACCATCAGCAGCGTGCAGGCC CTGGCCGTGTACTACTGCCAGCAGCACTACACCACCCCTCTGACCTTCGGCGCC GGCACCAAGCTGGAGC’TGAAG Hul2lO VK.l GACATCCAGATGACCCAGAGCCCTAGCAGCC’TGAGCGCTAGCGTGGGCGACAGGGTGACC U7 U7 ATCACCTGCAAGGCCAGCCAGGATGTGACCCCTGCCGTGGCCTGGTACCAGCAGAAGCCC GGCAAGGCCCCCAAGC’*GCTGATCTACAGCACCAGCAGCAGGTACACCGGCGTGCCCAGC AGGTTTAGCGGAAGCGGCAGCGGCACCGACT’*CACCTTCACCATCAGCAGCCTGCAGCCC GAGGACATCGCCACCTACTACTGCCAGCAGCACTACACCACCCCTCTGACCTTCGGCCAG GGCACCAAGCTGGAGA’TCAAG Hul2lO VK.la GACATCCAGATGACCCAGAGCCCTAGCAGCC’TGAGCGCTAGCGTGGGCGACAGGGTGACC U7 0 ATCACCTGCAAGGCCAGCCAGGATGTGACCCCTGCCGTGGCCTGGTACCAGCAGAAGCCC GGCAAGTCCCCCAAGC’*GCTGATCTACAGCACCAGCAGCAGGTACACCGGCGTGCCCAGC AGGTTTAGCGGAAGCGGCAGCGGCACCGACT’*CACCTTCACCATCAGCAGCCTGCAGCCC ATCGCCACCTACTACTGCCAGCAGCAC’TACACCACCCCTCTGACCTTCGGCCAG GGCACCAAGCTGGAGA’TCAAG GACATTCAGATGACCCAGTCCCCTAGCAGCCTG’*CCGCTTCCGTGGGCGACAGGGTGACC U7 \l ATCACCTGCAAGGCCAGCCAGGACGTGACACCTGCTGTGGCCTGGTATCAACAGAAGCCT GGCAAGGCTCCTAAGC’‘CCTGATCTACAGCACA’TCCTCCCGGTACACCGGAGTGCCCTCC AGGT"TAGCGGCAGCGGCTCCGGCACCGATTTCACCCTGACCATTTCCTCCCTGCAGCCC GAGGACTTCGCCACCTACTACTGCCAGCAGCAC’TACACCACACCCCTGACCTTCGGCCAG GGCACCAAGCTGGAGA’*CAAGCGG Hul2lO VK.2a GACATTCAGATGACCCAGTCCCCTAGCAGCCTG’*CCGCTTCCGTGGGCGACAGGGTGACC U7 00 ATCACCTGCAAGGCCAGCCAGGACGTGACACCTGCTGTGGCCTGGTATCAACAGAAGCCT GGCAAGGCTCCTAAGC’‘CCTGATCTACAGCACA’TCCTCCCGGTACACCGGAGTGCCCGAC AGGT"TACCGGCAGCGGCTCCGGCACCGATTTCACCCTGACCATTTCCTCCCTGCAGCCC GAGGACTTCGCCACCTACTACTGCCAGCAGCAC’TACACCACACCCCTGACCTTCGGCCAG AAGCTGGAGA’*CAAGCGG Hul2lO VK.2b GACATTCAGATGACCCAGTCCCCTAGCAGCCTG’*CCGCTTCCGTGGGCGACAGGGTGACC U7 ‘0 ATCACCTGCAAGGCCAGCCAGGACGTGACACCTGCTGTGGCCTGGTATCAACAGAAGCCT GGCCAGAGCCCTAAGC’‘CCTGATCTACAGCACA’TCCTCCCGGTACACCGGAGTGCCCGAC AGGT"TACCGGCAGCGGCTCCGGCACCGATTTCACCCTGACCATTTCCTCCCTGCAGCCC GAGGACTTCGCCACCTACTACTGCCAGCAGCAC’TACACCACACCCCTGACCTTCGGCCAG GGCACCAAGCTGGAGA’*CAAGCGG HulZlO VK .2C GACATTCAGATGACCCAGTCCCCTAGCAGCCTG’*CCGCTTCCGTGGGCGACAGGGTGACC ATCAGCTGCAAGGCCAGCCAGGACGTGACACCTGCTGTGGCCTGGTATCAACAGAAGCCT AGCCCTAAGC’‘CCTGATCTACAGCACA’TCCTCCCGGTACACCGGAGTGCCCGAC AGGT"TACCGGCAGCGGCTCCGGCACCGATTTCACCCTGACCATTTCCTCCCTGCAGCCC GAGGACTTCGCCACCTACTACTGCCAGCAGCAC’TACACCACACCCCTGACCTTCGGCCAG GGCACCAAGCTGGAGA’*CAAGCGG The zed VH and VK genes were produced synthetically and then respectively cloned into vectors containing the human gamma 1 and human kappa constant domains. The pairing of the human VH and the human VK created the 40 humanized antibodies (see Table 9).

Table 9. zed antibodies with their VH an VL regions D -68— [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r VH I u1210 I u1210 Hu1210 Hu1210 I u1210 I u1210 Hu1210 H.1 . VH.1b I u1210 Vk.1 I 1 I u1210-2 Hu1210-3 I u1210-4 I u1210 Vk.la I 7 I 8 Hu1210-9 I u1210-10 I 11 ””1”“ -_-- VH I u1210 I u1210 Hu1210 Hu1210 H.3 H.3a VH.4 .421 I u1210 Vk.1 I u1210-13 I u1210-14 Hu1210-15 I u1210-16I I u1210 Vk.la I u1210-18I u1210-19 -20 I u1210-21 I H.5 H.5a VH.5b .5c | u1210-26 | u1210-30 | u1210-35 | I u1210 I u1210 Hu1210 H.4c H.4d VH.4e I u1210-40I 41 Hu1210-42 Example 7: The antigen binding properties of humanized PD-Ll antibodies Binding property to recombinant human PD-L] To evaluate the antigen binding activity, the humanized antibodies were subjected to ELISA test. Briefly, microtiter plates were coated with human PD-Ll-Fc protein at 0.1 ug/ml in PBS, IOOuI/well at 4°C overnight, then blocked with well of 5% BSA. Five-fold dilutions ofhumanized antibodies starting from 10 ug/ml were added to each well and incubated for 1-2 hours at RT. The plates were washed with PBS/Tween and then incubate with goat-anti-mouse IgG antibody conjugated with Horse Radish dase (HRP) for 1 hour at RT. After washing, the plates were developed with TMB substrate and analyzed by spectrophotometer at OD 45 0- 630nm. As shown in all the humanized antibodies show comparable binding efficacy to human PD-Ll in contact to chimeric antibody.

Binding properly to mammalian expressed human PD-L] D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] wilksar ed set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar To evaluate the antigen binding property, the humanized antibodies were analyzed for its binding to mammalian expressed PD-Ll by FACS. Briefly, PDLl- CHOKl cells were firstly incubated with 5-fold serious diluted humanized antibodies starting at 2ug/ml at RT for 1 hour.

After wash by FACS buffer (PBS with 2% FBS), the alexa 488-anti-human IgG dy was added to each well and incubated at RT for 1 hour. The MFI ofAlexa 488 were evaluated by FACSAriaIII. As shown in the all the humanized dies can high ntly bind to PD-Ll expressed on mammalian cells, which was comparable with chimeric antibody.

To explore the g kinetics of the humanized antibody, this example performed the affinity g by using Octet Red 96. As shown in Table 10, -3, hu1210-8, hu1210-9, -14, hu1210-17, hulZlO-l and Hu1210-22 show better affinity, which is comparable with chimeric antibody.

Table 10. Aflinity ranking ofhumanized antibodies """"4605609m'f"'REM]m"“kéhii'lM'é'f'"'k'cii'éi'i'lé']'"E'“"AfiiifiécivW'fi"'"kij'kivij'W'"Em/Mg]“""ié'cii's'("1'/"s')'""§ Hu1210 ' 7.16E-09 3.94E+05 2.83E-03 : Hu1210-11 ‘ 4.18E-09 7.54E+04 3.15E-04 (mIgG) ‘ ‘1‘2‘ib“““““““1.075109“““““1.62905 “““““i.7éEL04“““““Hfiiiibiié “““““4(38510?)““““838904””“é‘.ééé£04””§ a i .......................... ........................................................... i Hu1210-1 4.25E-09 7.10E+04 3.02E-04 Hu1210-14 2.34E-09 8.41E+04 1.97E-04 Hu1210-2 3.23E-09 04 2.51E-04 Hu1210-15 4.45E-09 7.87E+04 3.50E-04 ‘ " " ' Hu1210-3 2.64E-09 8.62E+04 2.28E-04 Hu1210-16 3.14E-09 8.41904 2.64E-04 """H'Ji'z'ibizi""""""768905 """"7Iii90'4 """"5.46904“W"fidiiib'ii'7""""" ii0E-‘0é """"8117904""""i_‘g‘¢‘g.‘¢4““§ .Hfiiiidé‘w?“4.8é‘EH-0‘siw”"7.63904”""éi‘8éél04"‘5""Hfiiiibiié""3"‘4.505305"""752904”W‘élé7E—‘04Wfi Hu1210-7 09 8.45E+04 4.04E-04 Hu1210-19 2.50E-09 9.03E+04 04 ' " 1 Hu1210-8 1.64E-09 7.72904 1.27E-04 Hu1210-20 4515-09 8.87904 4.005-04 Hu1210-9 2335-09 8.37E+04 1.955-04 g Hu1210-21 3.12509 9.39904 2.935-04 ‘ " " ' Hu1210-10 7.03E-09 8.59E+04 6.04E-04 Hu1210-22 2.56E-09 9.00904 2.305-04 Fall kinetic aflinity 0f humanized antibodies by Biacore® The binding ofthe zed antibodies to recombinant PD-Ll protein (human PD-Ll- his taq) was tested by BIACORETM using a capture method. The HL1210-3 mouse mAb were captured using anti-mouse Fc antibody coated on a CMS chip. A series dilution ofhuman PD- Ll-his taq protein was injected over captured antibody for 3 mins at a flow rate of 25 ug/ml. The antigen was allowed to dissociate for 900s. All the experiment were carried out on a Biacore T200. Data analysis was carried out using Biacore T200 evaluation software and is shown in Table 11 below.

D [Annotation] wilksar None set by wilksar [Annotation] wilksar ionNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r Table I]. Aflinity by Biacore Hu1210-8 7.169E-5 7.671E-10 Hu1210-9 4.528E-5 4.594e-10 Hu1210-14 5.293E-5 43525-10 Hu1210-16 6.704E-5 6.720E-10 Hu1210-17 -5 -10 Hu1210-28 1.080E-4 8.378E-10 -3l 1.486E+5 1.168E-4 7.862E-10 Hu1210-36 1.461E+5 7.852E-5 5.376E-10 Hu1210-40 8.77E+04 1.3lE-04 1.49E-09 Hu1210-4l 9.17E+04 3.46E-05 3.78E-10 Hu1210-42 8.68E+04 7.53E-05 10 1210 Chimera 1.236E+5 3.265E-5 2.642E-10 Cross species activity To evaluate the binding nized antibodies to huPD-Ll, Mouse PD-Ll, Rat PD- Ll, Rhesus PD-Ll, the antibodies were performed for the ELISA testing. Briefly, microtiter plates were coated with human, mouse, rat and rhesus PD-Ll-Fc protein at l ug/ml in PBS, lOOul/well at 4°C ght, then d with lOOul/well of 5% BSA. Three-fold dilutions of humanized antibodies starting from 1 ug/ml were added to each well and incubated for 1-2 hours at RT. The plates were washed with PBS/Tween and then incubate with goat-anti-mouse IgG antibody conjugated with Horse Radish Peroxidase (HRP) for 1 hour at RT. After washing, the plates were developed with TMB substrate and analyzed by spectrophotometer at OD 45 0- 630nm. The Hu1210-4l antibody can bind to rhesus PD-Ll with lower affinity and cannot bind to rat and mouse PD-Ll (.

————— ECSO M 0.628nM Family member specificity To evaluate the binding ofhumanized anti-PD-Ll antibody to human B7 family and other immune checkpoint, the antibody was evaluate for its binding to B7-Hl (PD-Ll), B7-DC, D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar ation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar B7-l, B7-2, B7-H2, PD-l, CD28, CTLA4, ICOS and BTLA by ELISA. As shown in the Hu1210-4l antibody can only specifically g to B7-Hl (PD-Ll).

Example 8: Humanized antibodies blocked activity of human PD-Ll to PD-l Cell based receptor blocking assay To evaluate the blocking effect of humanized antibodies on human PD-Ll expressed on mammalian cells to bind to its or PD-l, the FACS-based receptor blocking assay was employed. Briefly, PDLl- CHOKl cells were firstly incubated with 3-fold serious diluted HL1210-3 mouse mAb starting at 20ug/ml at RT for 1 hour. After wash by FACS buffer (PBS with 2% FBS), the biotin-labeled huPD-l were added to each well and incubated at RT for 1 hour. Then, the StreptaVidin-PE were added to each well for 0.5 hour post twice wash with FACS buffer. The mean florescence intensity (MFI)of PE were evaluated by FACSAriaIII.

MFI oftesting dy % ofinhibition= (1 — MFI ofvehicle contorl )x 100% As shown in Table 12 below, Hu1210-3, Hu1210-9, Hu1210-8, Hu1210-14, Hu1210-17, Hu1210-19 and Hu1210-22 antibodies show comparable efficacy with chimeric antibody to blocking the binding of PD-Ll to PD-l.

Table [2. PD-] receptor blocking assay Bio-PD1(30ug/m|) TOP EC50 H1210 chimera 87.16 3.961 Hu1210—8 86.35 4.194 Hu1210—9 85.7 4.038 —16 88.02 5.436 Hu1210—17 80.88 4.424 —3 84.28 3.693 Hu1210—14 79.56 3.572 Hu1210—19 87.45 4.52 Hu1210—22 85.83 4.505 Hu1210—27 103.9 11.48 Hu1210—31 92.91 6.179 Hu1210-36 91.75 8.175 Receptor blocking assay by using recombinant human PD-L] There are two ors i.e. PD-l and B7-l for human PD-Ll. To eXplore the blocking property ofhumanized PD-Ll antibody to these two proteins, the n based receptor blocking assay was employed here. Briefly, microtiter plates were coated with human PD-Ll-Fc D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar protein at l ug/ml in PBS, lOOul/well at 4°C overnight, then blocked with 200ul/well of 5% BSA at 37 °C for 2 hr. 50ul biotin-labeled human c or B7-lvprotein and 5-fold dilutions of PD-Ll antibodies starting from 100nM at 50ul were added to each well and incubated for 1 hour at 37°C. The plates were washed with PBS/Tween and then te with Streptavidin- HRP for 1 hour at 37°C. After washing, the plates were ped with TMB substrate and analyzed by spectrophotometer at OD 450nm. As shown in and 11, Hu1210-41 can efficiently inhibit the binding of human PD-Ll to human PDl and B7-l.

Example 9: Humanized antibody promoted human T cell immune response.

Mixed lymphocyte Reaction assay To te the in vitro fianction of humanized antibodies, the se ofhuman T cells assessed in a mixed lymphocyte reaction setting. Human DCs were differentiated from CD14+ monocytes in the presence of GM-CSF and IL-4 for 7 days. CD4+ T cells isolated from another donor were then co-cultured with the DCs and serial dilutions of anti-PD-Ll blocking antibody.

At day 5 post-inoculation, the culture supernatant was assayed for IL-2 and IFNy production.

The results indicated that the -8, Hu1210-9, Hu1210-16 and Hu1210-17 antibodies can dose-dependently e IL-2 and IFNy production, suggesting anti-PD-Ll dies can promote human T cell response.

CMV recall assay To evaluate the in vitro fianction of zed antibodies, the response ofhuman T cells assessed in CMV recall assay. Human PBMCs were stimulated with l ug/ml CMV antigen in the presence of serious d humanized antibodies. As shown in and 13 the Hu1210-40, Hu1210-41 and Hu1210-17 can dose dependently promote the IFNy production.

Example 10: Tumor growth inhibition by D-Ll mAb.

Cells from the human lung adenocarcinoma cell line HCC827 will be grafted into NOD scid gamma (NSG) mice. NSG mice are NOD scid gamma deficient and the most immunodeficient mice making them ideal recipients for human tumor cell and PBMC grafting. days raft, human PBMCs will be transplanted into the tumor-bearing mice.

D [Annotation] wilksar None set by wilksar [Annotation] r MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar Approximately 20 days post-graft, once the tumor volume has reached lOO-lSOmm3, PD-Ll antibody will be administered to the mice every other day at 5 mg/kg. Tumor volume will be monitored every other day in conjunction with antibody administration. As shown in , Hu1210-3l can inhibit the tumor growth by 30% at 5mg/kg. Hu1210-4l dy can dose- dependently inhibit the tumor growth, while the tumor weight was also dose-dependently suppressed by Hu1210-4l antibody (). e 11. Computer Simulation of Further Variation and Optimization of the Humanized Antibodies It was contemplated that certain amino acid residues within the CDR regions or the ork regions could be changed to further improve or retain the activity and/or stability of the antibodies. Variants were tested, with a ational tool (VectorNTI, available at www.ebi.ac.uk/tools/msa/clustalo/), with t to their structural, conformational and fiinctional properties, and those (within the CDR regions) that showed es are listed in the tables blow.

Table 13. VH and VL CDRs and their variants suitable for inclusion in humanized antibodies Name Sequence SEQ ID NO: -—-EYDMS 61 -—-SEDMS 63 -syDMs 65 SYDMT _SYDMg Sequence SEQ ID NO: TISDGGG_YIYYSDS_VKG 2 AYIYYSDSVKG 68 "ISDGGPYIYYSDSVKG 69 "ISDGGGFIYYSDSVKG 7O "ISDGGGEIYYSDSVKG 71 "ISDGGGEIYYSDSVKG 72 "ISDGGGYIYYSDEVKG 73 "ISDGGGYIYYSDEVKG 74 D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by r [Annotation] wilksar None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar ed set by wilksar "ISDGGGYIYYSDSEKG 75 ‘ISDGGGYIYYSDSEKG "ISDGGGYIYYSDSMKG 77 Name Sequence SEQ ID NO: EFGKRYALDY (A) A RYA.L L} ,_< \1 OO IUIw m A RYPL L} '_< \1 L0 AAAA RYA.L L} ,_<RYA.LRYA.LRYA.

AA RYA.RYA.

RYA.

AAAiYA.fiaA.REA. UUUUUUUUU KKKKKKKKK A L} ,_< LOOOOOOOOOOOOOOOOOOOOO OkOOOflmU‘WbUJNHO SEQ ID NO: “PAVA llSequence SEQ ID NO: U)U) U)U) RYRY ,_ U) RY WIOI n—U) RYRY LOKOKOKOKOKOKO LOOO\1®U7>J>U) U)U) m mIOI RY U) m A,_< m m mNI m m m NIEIW S SS§E Sequence SEQ ID NO: QQHYTTPLT 6 [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by r [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar ine: hotspot mutation residues and their substitutes Example 12: fication of PD-Ll Epitope This study was conducted to identify amino acid residues involved in the binding of PD- L1 to the dies of the present disclosure.

An alanine-scan library of PD-Ll was ucted. Briefly, 217 mutant clones of PD-Ll were generated on Integral Molecular’s protein engineering rm. Binding ofHu1210-41 Fab to each variant in the PD-Ll mutation library was ined, in duplicate, by high- throughput flow cytometry. Each raw data point had background fluorescence subtracted and was normalized to reactivity with PD-Ll wild-type (WT). For each PD-Ll variant, the mean binding value was plotted as a fill’lCthl’l of sion (control anti-PD-Ll mAb reactivity). To identify preliminary critical clones (circles with crosses), thresholds (dashed lines) of >70% WT binding to control MAb and <30% WT reactivity to Hu1210-41 Fab were applied ().

Yl34, K162, and N183 of PDLl were identified as required residues for Hu1210-41 binding.

The low reactivity ofN183A clone with Hu1210-41 Fab suggests that it is the major energetic contributor to Hu1210-41 binding, with lesser butions by Y134 and K162.

The critical residues (spheres) were fied on a 3D PD-Ll structure (PDB ID# 5JDR, Zhang et al., 2017), rated in . These residues, Yl34, K162, and N183, ore, tute an epitope of PD-Ll responsible for binding to antibodies of various embodiments of the present disclosure.

It is interesting to note that Yl34, K162, and N183 are all located within the IgC domain ofthe PD-Ll protein. Both PD-l and PD-Ll ’s extracellular portions have an IgV domain and an IgC domain. It is commonly known that PD-Ll binds to PD-l through bindings between their IgV domains. Unlike such conventional antibodies, however, Hu1210-41 binds to the IgC domain, which would have been expected to be ineffective in inhibiting PD-l/PD-Ll binding.

D [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] wilksar Unmarked set by wilksar [Annotation] wilksar None set by wilksar [Annotation] wilksar MigrationNone set by wilksar [Annotation] r Unmarked set by wilksar This different epitope of Hu1210-4l, surprisingly, likely contributes to the ent activities of Hu1210-41. >l< * * The present disclosure is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the disclosure, and any compositions or methods which are fiinctionally equivalent are within the scope of this sure. It will be apparent to those skilled in the art that various modifications and variations can be made in the methods and compositions of the present disclosure without ing from the spirit or scope of the disclosure. Thus, it is intended that the present disclosure cover the ations and variations of this disclosure provided they come within the scope of the appended claims and their equivalents.

All publications and patent ations mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference 1003330702

Claims (13)

What is claimed is:

1. An isolated antibody or fragment thereof, wherein the dy or fragment thereof has specificity to a human Programmed death-ligand 1 (PD-L1) protein and comprises a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 2, or SEQ ID NO:2 with a substitution ed from D52E, G53A or G53V ing to Kabat numbering with reference to SEQ ID NO: 7, a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

2. The antibody or fragment thereof of claim 1, further comprising a heavy chain constant region, a light chain constant region, an Fc region, or the combination thereof.

3. The antibody or fragment thereof of claim 1 or 2, n the antibody or fragment thereof is a humanized antibody.

4. An isolated antibody or fragment thereof of claim 1, wherein the antibody or fragment thereof has specificity to a human Programmed death-ligand 1 (PD-L1) protein, comprising a heavy chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 7-26, and, comprising a light chain variable region sing an amino acid sequence selected from the group consisting of SEQ ID NO: 27-33.

5. The antibody or fragment thereof of claim 4, sing a heavy chain variable region sing the amino acid sequence of SEQ ID NO: 20 and a light chain le region comprising the amino acid sequence of SEQ ID NO: 28.

6. A composition comprising the antibody or fragment thereof of any one of claims 1-5 and a pharmaceutically acceptable carrier. 0702

7. An isolated cell comprising one or more polynucleotide ng the antibody or fragment thereof of any one of claims 1-5.

8. Use of an effective amount of the antibody or fragment thereof of any one of claims 1-5 in the preparation of a medicament for treating cancer or infection in a patient in need thereof .

9. The use of claim 8, wherein the cancer is selected from the group ting of bladder cancer, liver cancer, colon cancer, rectal cancer, endometrial cancer, leukemia, lymphoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, breast cancer, urethral cancer, head and neck cancer, intestinal cancer, stomach cancer, oesophageal cancer, ovarian cancer, renal cancer, ma, prostate cancer and thyroid .

10. An isolated bispecific antibody comprising a fragment of any one of claims 1-5, and a second antigen-binding fragment having specificity to a molecule on an immune cell.

11. The bispecific antibody of claim 10, wherein the molecule is selected from the group consisting of PD-1, CTLA-4, LAG-3, CD28, CD122, 4-1BB, TIM3, OX-40, OX40L, CD40, CD40L, LIGHT, ICOS, ICOSL, GITR, GITRL, TIGIT, CD27, VISTA, B7H3, B7H4, HEVM, BTLA, KIR, and CD47.

12. The bispecific antibody of claim 10 or 11, wherein the fragment and the second fragment each is independently selected from a Fab fragment, a single-chain le fragment (scFv), or a single-domain antibody.

13. The ific antibody of any one of claims 10-12, further comprising a Fc fragment.